细胞疗法製造市场（第七版）：趋势与预测至 2035 年 - 按细胞疗法类型、细胞来源、企业规模、製造商类型和地区划分

细胞疗法製造市场：概述

根据 Roots Analysis 预测，细胞疗法製造市场预计将以 7.7% 的复合年增长率增长，从目前的 71.72 亿美元增长至 2035 年的 140.17 亿美元。

细胞疗法製造市场 - 成长与趋势

多年来，许多技术创新和发现改变了医学领域。其中一项特别显着的进步是基于细胞疗法的出现。这些疗法展现出巨大的治疗潜力，并且在很大程度上避免了传统药物治疗中常见的许多毒性问题。目前，研究人员正在研究 1000 多种针对多种疾病的细胞和基因疗法候选药物。目前，全球已有约 45 种细胞疗法获得监管机构批准。此外，多家机构正致力于解决生产难题，确保这些创新疗法的持续成功。

细胞和基因疗法的生产是一个复杂的过程，需要在严格控制的无菌环境中进行，涉及多个关键步骤，包括免疫细胞（如 T 细胞和干细胞）的分离、修饰和扩增。每个步骤都需要使用专门的封闭系统，并严格遵守监管标准，以确保最终产品的安全性和有效性。各公司正致力于升级细胞处理和处理设备，改善辅助材料和细胞计数技术，并应对持续存在的物流挑战。因此，对于细胞疗法开发商而言，投资灵活的自动化技术以降低生产这些先进候选疗法过程中人为错误带来的风险变得越来越重要。这些改进有望帮助企业在维持产品品质和一致性的同时，有效控製成本。

成长驱动因素：市场扩张的策略基础

细胞治疗领域正经历快速成长，其特点是临床试验数量增加和监管审批范围扩大。随着越来越多的疗法从早期研究进入后期临床试验，患者获得这些疗法的机会也不断扩大。根据美国基因与细胞治疗学会 (ASGCT) 的报告，目前活跃的基因、细胞和 RNA 疗法研发管线共有 4,418 个项目（2,155 个基因疗法和 966 个非基因修饰细胞疗法），其中有 79 个新的基因疗法试验（57% 集中在肿瘤领域）。 RNA 疗法研发管线包括 2,155 种基因疗法和 966 种非基因修饰细胞疗法。此外，本季启动了 79 个新的基因疗法试验（57% 集中在肿瘤领域）和 27 个新的细胞疗法试验（74% 集中在非肿瘤领域）。预计随着本地细胞疗法生产设施的建立，这一进展将进一步加强。

市场挑战：发展面临的重大障碍

儘管市场需求强劲，但细胞疗法生产产业在将细胞疗法产品从实验室规模过渡到临床规模的过程中面临诸多挑战。这些障碍包括熟练劳动力短缺、监管合规问题以及缺乏先进的设施和基础设施。细胞疗法生产过程需要无菌、高等级的无尘室和严格的隔离监控，以确保产品的完整性和合规性。由于这些复杂的流程，扩大细胞疗法生产的规模可能极具挑战性。

细胞疗法生产市场：关键洞察

本报告深入分析了细胞疗法生产市场的现状，并指出了该行业的潜在成长机会。报告的主要发现包括：

• 目前，约有 200 家产业参与者从事细胞疗法生产，其中约 45% 的总部位于美国。

• 超过40%的产业参与者同时捐赠T细胞和干细胞。这是因为T细胞的排斥风险较低，而干细胞具有独特的再生和修復受损细胞及组织的能力。
• 目前，超过80家非行业公司从事细胞疗法製造，其中约55%位于美国。
• 约30%的非产业细胞疗法製造商成立于2001年之前，其中超过60%的公司同时使用自体细胞和异体细胞。
• 迄今为止，已有多个评估免疫细胞疗法的临床试验註册，其中大部分（65%）研究在亚太地区的各个试验中心进行。
• 近年来，各利害关係人之间建立的多元化合作关係也反映了市场对该领域日益增长的兴趣。事实上，超过55%的合作协议签署于2022年或以后。

• 70%的产业参与者正在透过建立新设施来扩展其现有的生产和技术能力，其中超过40%的设施专门用于T细胞生产。
• 超过55%的大型製药公司在该领域的投入是透过合作和伙伴关係推动的。 其中相当一部分已由百时美施贵宝公司实施。
• 目前营运的细胞疗法生产能力（以无尘室数量计算）约95%由业内企业拥有，其中规模最大的设施位于北美。
• 细胞疗法需求的成长得益于产品核准数量的增加、治疗方法的进步、医疗基础设施的扩建以及病患意识的提高。
• 由于高昂的资本成本和先进技术，细胞疗法製造业预计将以8.25%的复合年增长率成长。预计约60%的生产活动将外包给合约生产组织（CMO）。

• 癌症发生率上升、患者对个人化细胞疗法的需求变化以及细胞疗法製造技术的进步预计将推动市场稳步成长。
• 北美地区的快速技术创新预计将在今年占细胞​​疗法製造市场的重要占有率。
• 受美国领先企业开发的已获批准的细胞疗法的成功推动，商业细胞疗法製造市场预计将以12.93%的复合年增长率增长。
• 鑑于细胞疗法在临床上的快速成功和不断增长的需求，以及其在治疗血液癌症等疾病方面的广泛潜力，该行业已为未来的增长做好了充分准备。

细胞疗法製造市场

市场规模与机会分析依下列参数细分：

按细胞疗法类型

• CAR-T 细胞疗法
• 干细胞疗法
• TCR 疗法
• TIL 疗法
• 树突细胞疗法
• 其他

依细胞来源

• 自体细胞
• 异体细胞
• 未定义细胞

依企业规模

• 临床规模
• 商业规模

依製造商类型

• 内部製造商
• 合约製造组织

按地区

• 北部美洲
• 美国
• 加拿大
• 欧洲
• 法国
• 德国
• 义大利
• 西班牙
• 英国
• 其他

亚太及世界其他地区

• 阿根廷
• 澳大利亚
• 巴西
• 中国
• 印度
• 以色列
• 日本
• 新加坡
• 南非
• 韩国
• 台湾

细胞疗法製造市场：主要细分市场

CAR-T 细胞疗法占细胞疗法製造市场最大占有率

今年，CAR-T 细胞疗法细分市场占了最大的市场占有率（约 65%），这主要得益于其疗程更短、输注次数更少。此外，包括自然杀手细胞疗法和基因修饰细胞疗法在内的其他细胞疗法细分市场，预计在预测期内将维持16.15%的复合年增长率。自然杀手细胞良好的安全性降低了移植物抗宿主疾病等併发症的风险。此外，其作为现成疗法的潜力也推动了这一成长。

自体细胞将占细胞疗法生产市场最大占有率

到2035年，自体细胞疗法预计将占细胞疗法生产市场更大的占有率，超过50%。此外，预计该细分市场在整个预测期内将呈现显着成长。这主要是因为自体细胞疗法生产专注于使用患者自身的细胞，从而最大限度地降低了免疫排斥的风险，而免疫排斥可能导致移植物抗宿主疾病等严重併发症。

北美将占市场主导地位，占有率最大

根据我们的市场预测，预计到2025年，北美将维持细胞疗法生产市场最大的占有率，约占45%。此外，预计到2035年，北美将实现9.70%的相对较快的成长率。值得注意的是，该市场约60%的市占率来自临床细胞疗法生产。在临床细胞疗法生产领域，美国是製造商的中心，拥有鼓励创新的监管框架和高技能的劳动力。这种区域集中化使得细胞疗法的生产能够从早期研发到商业化供应高效扩展。

细胞疗法生产市场的主要参与者

• Advanced Therapies
• AGC Biologics
• Astellas Pharma
• Catalent
• Charles River Laboratories
• City of Hope
• Clinical Cell and Vaccine Production Facility (CVPF)
• Evotec
• Fraunhofer Institute for Cell Therapy and Immunology
• ImmunityBio
• Lonza
• Merck Millipore
• Miltenyi Biotec
• Minaris Advanced Therapies
• 纽卡斯尔先进疗法
• 英国国家医疗服务体系血液与移植中心
• OBiO Tech
• Pharmaron
• Rayne 细胞治疗中心
• Resilience
• Sartorius
• 苏格兰国家输血服务中心 (SNBTS) 细胞治疗中心
• SK pharmteco（SK 株式会社子公司）
• Takara Bio
• 赛默飞世尔科技

细胞治疗製造市场：研究范围

• 市场规模和机会分析：本报告对细胞治疗製造市场进行了详细分析，重点关注以下关键市场细分：[A] 细胞治疗类型，[B] 细胞来源，[C] 营运规模，[D] 製造商类型，以及 [E] 地理区域。
• 产业参与者 - 市场概况 1：详细概述细胞治疗製造领域企业的当前市场概况，包括以下资讯：[A] 成立年份，[B] 公司规模，[C] 总部所在地，[D] 生产设施所在地，[E] 提供的免疫细胞类型，[F] 细胞来源，[G] 业务规模，以及服务 [H] 提供的其他类型。
• 非产业参与者 - 市场概况 2：详细概述细胞治疗製造领域非产业参与者的当前市场概况，以及以下相关参数的资讯：[A] 成立年份，[B] 公司规模，[C] 总部所在地，[D] 生产设施所在地，[E] 提供的免疫细胞类型，[F] 细胞来源，[G] 业务规模，以及 [H] 业务规模提供的其他类型。
• 监管环境：概述北美（主要指美国）、欧洲和亚洲（主要指日本和中国）细胞疗法生产相关的法规。包括对全球主要监管机构授予生产设施的各种认证和批准的分析。
• 案例研究 1：概述全球各机构发布的旨在推进细胞疗法生产流程的各种路线图。
• 案例研究 2：本报告详细阐述了技术自动化在优化目前使用封闭式和一次性系统的生产流程中的具体作用。此外，也基于两个案例研究，展示了自动化设备开发的各个阶段。
• 公司简介：本报告根据[A]成立年份、[B]总部所在地、[C]产品组合、[D]近期发展和[E]未来展望，详细介绍了北美、欧洲和亚太地区细胞疗法生产领域的主要行业和非行业参与者。
• 临床试验分析：本报告基于多个相关参数分析已完成、正在进行和计划中的临床试验，这些参数包括研究註册年份、入组患者人数、研究状态、研究阶段、患者性别、研究设计、分配方法、干预模型、盲法类型、申办方/合作方类型、主要参与者（按进行的临床试验数量划分）以及试验的地域分布。
• 合作关係：本报告基于多个相关参数详细分析细胞治疗生产商之间的合作关係，这些参数包括合作年份、合作类型、提供的免疫细胞类型、业务规模以及主要参与者（按合作数量划分）。本章也涵盖了市场合作活动的区域分布。
• 近期扩张趋势：除了对行业内已公布的扩张计划进行详细分析外，本分析还基于以下几个相关参数：[A] 扩张年份，[B] 扩张进度，[C] 扩张类型，[D] 设施位置，[E] 投资额，[F] 提供的免疫细胞类型，[G] 提供的服务类型，以及参与者 [H] 最活跃的类型，以及参与者的活跃类型，以及参与者的最活跃。
• 大型製药公司举措：本部分讨论了大型製药公司针对细胞疗法生产开展的各项举措，包括：[A] 举措年份，[B] 举措类型，[C] 举措数量，[D] 合作类型，[E] 合作数量，[F] 设施扩建类型，[G] 设施扩建数量，[H] 设施合作数量，[F] 设施扩建类型，[G] 设施扩建[L] 企业规模。
• 产能分析：细胞疗法生产总装置容量的估算。该分析基于公开信息，并结合利益相关者提供的信息进行计算，确定了可用产能在洁净室面积和洁净室数量方面的分布。
• 需求分析：对细胞疗法的年度商业和临床需求进行基于资讯的估算。对以下相关参数进行横断面分析：[A] 细胞疗法类型，[B] 主要地理区域。
• 成本分析：深入分析可能影响细胞疗法价格的各种因素。重点介绍製造商为确定产品价格而采用的各种模型/方法。
• 内部生产与外包决策框架：定性分析，重点介绍细胞疗法开发商在决定是内部生产产品还是利用合约生产组织 (CMO) 的服务时应考虑的各种因素。
• 总拥有成本：基于公司规模，对细胞疗法生产机构 20 年的总拥有成本进行详细分析。
• SWOT 分析：讨论优势、劣势、机会和威胁，并确定每个 SWOT 参数对市场动态的相对影响。

目录

第一章：引言

第二章：研究方法

第三章：市场动态

• 章节概述
• 预测研究法
• 市场估值框架
• 预测工具与技术
• 关键考虑因素
• 局限性

第四章：宏观经济指标

第五章：摘要整理

第六章：引言

• 章节概述
• 细胞疗法简介
• 细胞疗法生产概述
• 细胞疗法生产模式
• 细胞疗法生产的可扩展性流程
• 细胞疗法生产者类型
• 细胞疗法生产的主要挑战
• 影响细胞疗法生产的关键因素
• 细胞疗法生产自动化
• 细胞疗法生产供应链
• 未来展望

第七章：细胞疗法生产者（产业参与者）：市场概况

• 章节概述
• 产业参与者：市场概况

第八章：细胞疗法生产者（非产业参与者）：市场概况

• 章节概述
• 非行业参与者：市场概况

第九章：监理环境

• 章节概述
• 当前状况
• 细胞疗法监管机构生产製造
• 早期细胞疗法生产指南概要
• 早期细胞疗法生产面临的挑战
• 监管指南的区域差异

第十章：案例研究：克服细胞疗法生产相关挑战的路线图

• 章节概述
• 美国路线图
• 其他地区路线图

第十一章：案例研究：细胞疗法生产中的自动化技术

• 章节概述
• 细胞疗法生产流程自动化
• 成长驱动因素与障碍
• 个案研究

第十二章：产业参与者公司简介

• 章节概述
• 北美服务提供者
  • AGC 生物製剂
  • 康泰伦特
  • 查尔斯河实验室
  • 免疫生物
  • 默克密理博
  • 米纳里斯先进疗法
  • 韧性
  • SK pharmteco（SK Inc. 的子公司）
  • 赛默飞世尔科技
• 欧洲服务提供者
  • Evotec
  • 龙沙
  • 美天旎生物科技
  • 赛多利斯
• 亚太地区服务提供者
  • 安斯泰来製药
  • 奥比奥科技
  • Pharmaron
  • Takara Bio

第13章 公司简介：产业外的公司

• 章节概述
• 希望之城
• 临床细胞和疫苗生产设施 (CVPF)
• 弗劳恩霍夫细胞治疗与免疫学研究所
• 纽卡斯尔先进疗法
• 英国国家医疗服务体系血液与移植中心
• 雷恩细胞治疗中心（伦敦国王学院）
• 苏格兰国家输血服务中心 (SNBTS) 细胞治疗设施

第14章：细胞治疗製造领域的非营利组织

• 章节概述
• 细胞治疗製造：非营利组织
• 细胞疗法生产：国际会议

第15章：临床试验分析

• 章节概述
• 研究范围与方法
• 细胞疗法：临床试验分析

第16章：伙伴关係与合作

第17章：近期扩张

• 章节概述
• 扩张型
• 细胞疗法生产：近期扩张

第18章：主要药厂的措施

• 章节概述
• 细胞疗法生产：主要製药公司列表
• 细胞疗法生产：主要製药公司措施列表

第19章 产能分析

第20章：需求分析

第21章：成本分析

• 章节概述
• 导致细胞疗法价格高的因素
• 细胞疗法定价模型
• 细胞疗法成本优化
• 细胞疗法合约生产组织的作用
• 细胞疗法报销考量

第22章：自製或外购决策架构

• 章节概述
• 假设和关键参数
• 细胞疗法生产：自製或外购决策

第23章：细胞疗法生产组织的总拥有成本

第24章：SWOT分析

第25章：研究与分析

第26章：全球细胞疗法製造市场

第27章：细胞疗法製造市场（依细胞疗法类型划分）

第28章：细胞疗法製造市场（依细胞来源划分）

第29章：细胞疗法製造市场（依企业规模划分）

第30章 细胞疗法生产市场（依生产商类型划分）

第31章 细胞疗法生产市场（按地区划分）

第32章 细胞疗法生产市场机会分析：北美

第33章 细胞疗法生产市场机会分析：欧洲

第34章 细胞疗法生产市场机会分析：亚太地区及世界其他地区

第35章 结论

第36章 高阶主管洞察

附录一：表格资料

附录二：公司与组织列表

Cell Therapy Manufacturing Market: Overview

As per Roots Analysis, the cell therapy manufacturing market is estimated to grow from USD 7,172 million in the current year to USD 14,017 million by 2035, at a CAGR of 7.7% during the forecast period, till 2035.

Cell Therapy Manufacturing Market: Growth and Trends

Over the years, numerous technological innovations and discoveries have transformed the field of medicine. One notable advancement is the emergence of cell-based therapies, which have shown substantial therapeutic promise and are largely free from many of the toxicity issues linked to traditional pharmacological treatments. Researchers are exploring over 1,000 cell and gene therapy candidates targeting a wide range of disease indications. Of these, approximately 45 cell-based therapies have already received approval from various global regulatory agencies. In addition, several organizations are implementing initiatives to tackle manufacturing challenges and ensure the ongoing success of these innovative therapies.

The manufacturing of cell and gene therapies is a complex process that occurs in a meticulously controlled, contamination-free environment and involves multiple critical stages, such as isolating, modifying, and expanding immune cells, including T-cells and stem cells. Each of these stages demand the use of specialized closed systems and rigorous compliance with regulatory standards to guarantee the safety and effectiveness of the final products. Companies are focused on enhancing cell handling and processing equipment, improving ancillary materials and cell counting techniques, and addressing current logistical challenges. Consequently, it is becoming increasingly essential for cell therapy developers to invest in flexible and automated technologies to mitigate the risks associated with human error during the production of these advanced therapeutic candidates. These improvements are expected to help companies maintain quality and consistency of products while keeping costs manageable.

Growth Drivers: Strategic Enablers of Market Expansion

The field of cell therapy is experiencing rapid growth, characterized by an increase in clinical trial and a rise in regulatory approvals. With a greater number of therapies advancing from initial research to late-stage clinical trials, patients have more opportunities to access these treatments. A report from the American Society of Gene & Cell Therapy (ASGCT) indicates that there are currently 4,418 active programs in the combined gene, cell, and RNA therapy pipeline, comprising 2,155 gene therapies and 966 non-genetically modified cell therapies, along with 79 new gene therapy trials (57% focused on oncology) and 27 new cell therapy trials (74% in non-oncology) that were initiated during that quarter. This progress will be bolstered by the establishment of local manufacturing facilities for cell therapies.

Market Challenges: Critical Barriers Impeding Progress

Despite strong demand, the cell therapy manufacturing sector faces multiple challenges in moving cell-based therapy products from the lab to clinical scale. These obstacles include a shortage of skilled workers, regulatory compliance issues, and insufficient advanced facilities and infrastructure. The manufacturing processes for cell therapy necessitate sterile, high-grade clean rooms and strict monitoring of containment levels to ensure product integrity and compliance. Due to these intricate procedures, scaling up cell therapy manufacturing can be considerably difficult.

Cell Therapy Manufacturing Market: Key Insights

The report delves into the current state of the cell therapy manufacturing market and identifies potential growth opportunities within industry. Some key findings from the report include:

• Currently, close to 200 industry players are engaged in cell therapy manufacturing; of these, ~45% of players are headquartered in the US.

• More than 40% of industry players offer both T-cells and stem cells, as T-cells have a lower risk of rejection while stem cells possess a unique ability to regenerate or repair damaged cells and tissues.
• More than 80 non-industry players are currently engaged in the manufacturing of cell therapies; around 55% of these players are based in the US.
• ~30% of the non-industry cell therapy manufacturers were established before 2001; among these, more than 60% of players utilize both autologous and allogeneic source of cells.
• Several clinical trials evaluating immune cell therapies have been registered till date; majority (65%) of these studies have been conducted across various trial sites in Asia-Pacific.
• The rising interest in this market is reflected from the diverse partnerships established among various stakeholders in the recent past; in fact, >55% of the deals have been inked post 2022.

• 70% of the industry players have expanded their existing capacities and capabilities through establishment of new facilities; more than 40% facilities are dedicated to manufacturing of T cells.
• Over 55% of major big pharma initiatives in this domain have been pursued through partnerships and collaborations; of these, a sizeable proportion of the initiatives were undertaken by Bristol-Myers Squibb.
• ~95% of the current installed cell therapy manufacturing capacity (in terms of number of cleanrooms) is presently available with industry players; maximum capacity is installed in facilities based in North America.
• The rising demand for cell-based therapies stems from increasing product approvals, advancing therapies, expanding healthcare infrastructure, and growing patient awareness.
• The cell therapy manufacturing domain is poised to grow at a CAGR of 8.25%, owing to high capital costs and advanced technologies; ~60% of manufacturing activities are expected to be outsourced to CMOs.

• Owing to the rising prevalence of cancer, and shift in patient preferences towards tailored cell therapies and advancements in cell therapy manufacturing technologies, the market is poised for a steady growth in the future.
• North America is expected to capture a significant share of the cell therapy manufacturing market in the current year owing to rapid innovation of technologies within the region.
• Driven by the success of approved cell therapies developed by prominent players in the US, the commercial cell therapy manufacturing market is expected to grow at CAGR of 12.93%.
• Given the rapid clinical success and rising demand for cell therapies, coupled with their extensive potential in treating disorders like blood cancer, the industry is well-positioned for future growth.

Cell Therapy Manufacturing Market

The market sizing and opportunity analysis has been segmented across the following parameters:

By Type of Cell Therapy

• CAR-T Cell Therapy
• Stem Cell Therapy
• TCR Therapy
• TIL Therapy
• Dendritic Cell Therapy
• Others

By Source of Cells

• Autologous Cells
• Allogeneic Cells
• Unspecified Cells

By Scale of Operation

• Clinical Scale
• Commercial Scale

By Type of Manufacturer

• In-house Manufacturers
• Contract Manufacturing Organizations

By Geographical Regions

• North America
• US
• Canada
• Europe
• France
• Germany
• Italy
• Spain
• UK
• Rest of Europe

Asia-Pacific and Rest of the World

• Argentina
• Australia
• Brazil
• China
• India
• Israel
• Japan
• Singapore
• South Africa
• South Korea
• Taiwan

Cell Therapy Manufacturing Market: Key Segments

CAR-T Cell Therapies Accounts for the Largest Share in the Cell Therapy Manufacturing Market

In the present year, the CAR-T cell therapies segment holds the largest market share (approximately 65%), attributed to the shorter treatment regimen that requires fewer infusions. Further, the segment of other cell therapies, which includes natural killer cell therapies and gene-modified cell therapies, is anticipated to experience a higher compound annual growth rate (CAGR) of 16.15% throughout the forecast period. The favorable safety profile of NK cells reduces the risk of conditions such as graft-versus-host disease. Additionally, their potential to function as off-the-shelf therapies propels this growth.

Autologous Cells Hold the Highest Share in the Cell Therapy Manufacturing Market

In 2035, the autologous segment is projected to hold a larger share of the cell therapy manufacturing market, accounting for over 50%. Additionally, this segment is expected to experience a notable growth rate throughout the forecast period. This can be attributed mainly to the focus of autologous cell therapy manufacturing on the patient's own cells, which minimizes the risk of immune rejection that can result in severe complications such as graft-versus-host disease.

North America Dominates the Market by Securing Highest Share

Based on our market forecast, North America is expected to hold the largest share of the cell therapy manufacturing market, accounting for approximately 45% by 2025. Further, we anticipate that North America will experience a comparatively faster growth rate of 9.70% until 2035. It is important to highlight that around 60% of this market derives from clinical cell therapy manufacturing. In the clinical cell therapy manufacturing sector, the U.S. has become a central hub for manufacturers, bolstered by their innovation-friendly regulatory framework and highly qualified workforce. This regional concentration enables efficient scaling of cell therapy production, from initial development stages to commercial supply.

Primary Research Overview

The opinions and insights presented in the market report were also influenced by discussions held with senior stakeholders in the industry. The market report includes detailed transcripts of interviews conducted with the following individuals:

• Marketing Manager, Cell Therapy, Mid-sized Company, Australia
• Director, UK
• Marketing Director, Small Company, Belgium
• Management Board Vice-President, Large Company, Poland
• Senior Director of Sales Advanced Therapies; Vice President of Marketing, Small Company, US
• Business Administration Department Manager, Mid-sized Company, Japan
• Chief Business Officer, Small Company, Netherlands
• Director of Finance and Facility Operations, US
• Senior Director, Very Large Company, Japan
• Chief Executive Officer, Mid-sized Company, UK
• Former Chief Technical Officer, Large Company, US
• Former Chief Executive Officer, Small Company, Netherlands
• Former General Manager, Small Company, France
• Chief Executive Officer, Large Company, China
• Executive Vice President Research and Development, Small Company, Israel
• Former Business Development Manager, Mid-sized Company, UK
• Professor and American Red Cross Chair in Transfusion Medicine, US
• Former Co-Founder and Chief Executive Officer, Small Company, Singapore
• Former Manager, Business Development and Operations-cGMP Manufacturing Unit, Mid-sized Company, Canada
• Manager of Business Development, Small Company, US
• Former Department Leader, Cell Therapy Innovation and Development, Mid-sized Company, France
• Former Chief Executive Officer, Mid-sized Company, Australia
• Chief Executive Officer, Small Company, Netherlands

Example Players in Cell Therapy Manufacturing Market

• Advanced Therapies
• AGC Biologics
• Astellas Pharma
• Catalent
• Charles River Laboratories
• City of Hope
• Clinical Cell and Vaccine Production Facility (CVPF)
• Evotec
• Fraunhofer Institute for Cell Therapy and Immunology
• ImmunityBio
• Lonza
• Merck Millipore
• Miltenyi Biotec
• Minaris Advanced Therapies
• Newcastle Advanced Therapies
• NHS Blood and Transplant
• OBiO Tech
• Pharmaron
• Rayne Cell Therapy Suite
• Resilience
• Sartorius
• Scottish National Blood Transfusion Service (SNBTS) Cellular Therapy Facility
• SK pharmteco (Subsidiary of SK Inc.)
• Takara Bio
• Thermo Fisher Scientific

Cell Therapy Manufacturing Market: Research Coverage

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the cell therapy manufacturing market, focusing on key market segments, including [A] type of cell therapy, [B] source of cells, [C] scale of operation, [D] type of manufacturer, and [E] geographical regions.
• Industry Players - Market Landscape 1: A detailed overview of the current market landscape of companies engaged of industry players in cell therapy manufacturing domain, featuring information on, along with information on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] location of manufacturing facility, [E] type of immune cell offered, [F] source of cells, [G] scale of operation, and [H] type of additional service offered.
• Non-industry Players - Market Landscape 2: A detailed overview of the current market landscape of non-industry players in cell therapy manufacturing domain along with information on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] location of manufacturing facility, [E] type of immune cell offered, [F] source of cells, [G] scale of operation, and [H] type of additional service offered.
• Regulatory Landscape: An overview of cell therapy manufacturing related regulations across various geographies, including North America (focusing on the US), Europe and Asia (focusing on Japan and China), featuring an analysis of the diverse certifications / accreditations awarded to the manufacturing facilities by important regulatory bodies across the globe.
• Case Study 1: An overview of the various roadmaps published by different agencies across the globe in order to provide strategies to advance cell therapy manufacturing process.
• Case Study 2: A detailed role of technology automation in cell therapy manufacturing in order to optimize the current manufacturing practices with the use of closed and single use systems. Further, it features a roadmap that provides information on the steps to develop automation devices, supported by two case studies
• Company Profiles: In-depth profiles of prominent industry and non-industry players in North America, Europe and Asia-Pacific that are involved in cell therapy manufacturing based on [A] year of establishment, [B] location of headquarters, [C] product portfolio, [D] recent developments and [E] an informed future outlook.
• Clinical Trial Analysis: An analysis of completed, ongoing and planned clinical trial, based on several relevant parameters, such as trial registration year, enrolled patient population, trial status, trial phase, patient gender, study design, type of allocation, intervention model, type of masking, type of sponsor / collaborator most active players (in terms of number of clinical trial conducted) and geographical distribution of trials.
• Partnerships and Collaborations: An in-depth analysis of the partnerships and collaborations that have been inked by cell therapy manufacturers, based on several relevant parameters, such as year of partnership, type of partnership, type of immune cell offered, scale of operation and most active players (in terms of number of partnerships). The chapter also highlights the regional distribution of partnership activity in this market.
• Recent Expansions: A detailed analysis of expansions reported in the domain, along with analysis on several relevant parameters, such as [A] year of expansion, [B] status of expansion, [C] type of expansion, [D] location of facility, [E] amount invested, [F] type of immune cell offered, [G] type of service offered and [H] most active players.
• Big Pharma Initiatives: An in-depth analysis of the various cell therapy manufacturing focused initiatives undertaken by big pharma players, based on several relevant parameters, such as [A] year of initiative, [B] type of initiative, [C] number of initiatives, [D] type of partnership, [E] number of partnerships, [F] type of facility expansion, [G] number of facility expansions, [H] region of facility expansion, [I] number of mergers and acquisitions, [J] number of funding and investment, [K] type of immune cell offered, and [L]scale of operation.
• Capacity Analysis: An estimate an estimate of the overall installed capacity for the manufacturing of cell-based therapies, based on information reported by various industry stakeholders in the public domain, highlighting the distribution of the available capacity in terms of cleanroom area and number of cleanrooms.
• Demand Analysis: An informed estimate of the annual commercial and clinical demand for cell therapies, across several relevant parameters, such as [A] type of cell therapy, and [B] key geographical regions.
• Cost Price Analysis: A detailed analysis of various factors that are likely to influence the price of cell-based therapies, featuring different models / approaches adopted by manufacturers in order to determine the price of their proprietary offerings.
• Make Versus Buy Decision Making Framework: A qualitative analysis that highlights the various factors that need to be taken into consideration by cell therapy developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
• Total Cost of Ownership: A detailed total cost of ownership analysis based on company size, for cell therapy manufacturing organizations, over a period of 20 years.
• SWOT Analysis: a discussion on strength, weaknesses, opportunities and threats, highlighting the relative effect of each SWOT parameter on the overall market dynamics.

Key Questions Answered in this Report

• Which are the leading companies in cell therapy manufacturing market?
• Which region dominates the cell therapy contract manufacturing market?
• What are the key trends observed in the cell therapy manufacturing market?
• What factors are likely to influence the evolution of this market?
• What are the primary challenges faced by cell therapy contract manufacturers?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
• The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
• The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
• The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
• The report allows for more effective communication with the audience and in building strong business relations.

Additional Benefits

• Complementary PPT Insights Pack
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Market Share Insights
• 1.3. Key Market Insights
• 1.4. Report Coverage
• 1.5. Key Questions Answered
• 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
  • 2.2.1. Market Landscape and Market Trends
  • 2.2.2. Market Forecast and Opportunity Analysis
  • 2.2.3. Comparative Analysis
• 2.3. Database Building
  • 2.3.1. Data Collection
  • 2.3.2. Data Validation
  • 2.3.3. Data Analysis
• 2.4. Project Methodology
  • 2.4.1. Secondary Research
    • 2.4.1.1. Annual Reports
    • 2.4.1.2. Academic Research Papers
    • 2.4.1.3. Company Websites
    • 2.4.1.4. Investor Presentations
    • 2.4.1.5. Regulatory Filings
    • 2.4.1.6. White Papers
    • 2.4.1.7. Industry Publications
    • 2.4.1.8. Conferences and Seminars
    • 2.4.1.9. Government Portals
    • 2.4.1.10. Media and Press Releases
    • 2.4.1.11. Newsletters
    • 2.4.1.12. Industry Databases
    • 2.4.1.13. Roots Proprietary Databases
    • 2.4.1.14. Paid Databases and Sources
    • 2.4.1.15. Social Media Portals
    • 2.4.1.16. Other Secondary Sources
  • 2.4.2. Primary Research
    • 2.4.2.1. Types of Primary Research
      • 2.4.2.1.1. Qualitative Research
      • 2.4.2.1.2. Quantitative Research
      • 2.4.2.1.3. Hybrid Approach
    • 2.4.2.2. Advantages of Primary Research
    • 2.4.2.3. Techniques for Primary Research
      • 2.4.2.3.1. Interviews
      • 2.4.2.3.2. Surveys
      • 2.4.2.3.3. Focus Groups
      • 2.4.2.3.4. Observational Research
      • 2.4.2.3.5. Social Media Interactions
    • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
      • 2.4.2.4.1. Company Executives (CXOs)
      • 2.4.2.4.2. Board of Directors
      • 2.4.2.4.3. Company Presidents and Vice Presidents
      • 2.4.2.4.4. Research and Development Heads
      • 2.4.2.4.5. Technical Experts
      • 2.4.2.4.6. Subject Matter Experts
      • 2.4.2.4.7. Scientists
      • 2.4.2.4.8. Doctors and Other Healthcare Providers
    • 2.4.2.5. Ethics and Integrity
      • 2.4.2.5.1. Research Ethics
      • 2.4.2.5.2. Data Integrity
  • 2.4.3. Analytical Tools and Databases
• 2.5. Robust Quality Control

3. MARKET DYNAMICS

• 3.1. Chapter Overview
• 3.2. Forecast Methodology
  • 3.2.1. Top-down Approach
  • 3.2.2. Bottom-up Approach
  • 3.2.3. Hybrid Approach
• 3.3. Market Assessment Framework
  • 3.3.1. Total Addressable Market (TAM)
  • 3.3.2. Serviceable Addressable Market (SAM)
  • 3.3.3. Serviceable Obtainable Market (SOM)
  • 3.3.4. Currently Acquired Market (CAM)
• 3.4. Forecasting Tools and Techniques
  • 3.4.1. Qualitative Forecasting
  • 3.4.2. Correlation
  • 3.4.3. Regression
  • 3.4.4. Extrapolation
  • 3.4.5. Convergence
  • 3.4.6. Sensitivity Analysis
  • 3.4.7. Scenario Planning
  • 3.4.8. Data Visualization
  • 3.4.9. Time Series Analysis
  • 3.4.10. Forecast Error Analysis
• 3.5. Key Considerations
  • 3.5.1. Demographics
  • 3.5.2. Government Regulations
  • 3.5.3. Reimbursement Scenarios
  • 3.5.4. Market Access
  • 3.5.5. Supply Chain
  • 3.5.6. Industry Consolidation
  • 3.5.7. Pandemic / Unforeseen Disruptions Impact
• 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

• 4.1. Chapter Overview
• 4.2. Market Dynamics
  • 4.2.1. Time Period
    • 4.2.1.1. Historical Trends
    • 4.2.1.2. Current and Forecasted Estimates
  • 4.2.2. Currency Coverage
    • 4.2.2.1. Major Currencies Affecting the Market
    • 4.2.2.2. Factors Affecting Currency Fluctuations
    • 4.2.2.3. Impact of Currency Fluctuations on the Industry
  • 4.2.3. Foreign Currency Exchange Rate
    • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
    • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 4.2.4. Recession
    • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
  • 4.2.5. Inflation
    • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
  • 4.2.6. Interest Rates
    • 4.2.6.1. Interest Rates and Their Impact on the Market
    • 4.2.6.2. Strategies for Managing Interest Rate Risk
  • 4.2.7. Commodity Flow Analysis
    • 4.2.7.1. Type of Commodity
    • 4.2.7.2. Origins and Destinations
    • 4.2.7.3. Values and Weights
    • 4.2.7.4. Modes of Transportation
  • 4.2.8. Global Trade Dynamics
    • 4.2.8.1. Import Scenario
    • 4.2.8.2. Export Scenario
    • 4.2.8.3. Trade Policies
    • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
    • 4.2.8.5. Impact of Trade Barriers on the Market
  • 4.2.9. War Impact Analysis
    • 4.2.9.1. Russian-Ukraine War
    • 4.2.9.2. Israel-Hamas War
  • 4.2.10. COVID Impact / Related Factors
    • 4.2.10.1. Global Economic Impact
    • 4.2.10.2. Industry-specific Impact
    • 4.2.10.3. Government Response and Stimulus Measures
    • 4.2.10.4. Future Outlook and Adaptation Strategies
  • 4.2.11. Other Indicators
    • 4.2.11.1. Fiscal Policy
    • 4.2.11.2. Consumer Spending
    • 4.2.11.3. Gross Domestic Product
    • 4.2.11.4. Employment
    • 4.2.11.5. Taxes
    • 4.2.11.6. Stock Market Performance
    • 4.2.11.7. Cross Border Dynamics
• 4.3. Conclusion

5. EXECUTIVE SUMMARY

• 5.1. Executive Summary: Market Landscape
• 5.2. Executive Summary: Market Trends
• 5.3. Executive Summary: Market Forecast and Opportunity Analysis

6. INTRODUCTION

• 6.1. Chapter Overview
• 6.2. Introduction to Cell-based Therapies
  • 6.2.1. Comparison of Cell-based Therapies and Other Biotechnology Products
  • 6.2.2. Classification of Advanced Therapy Medicinal Products (ATMPs)
  • 6.2.3. Current Market Landscape of ATMPs
• 6.3. Overview of Cell Therapy Manufacturing
• 6.4. Cell Therapy Manufacturing Models
  • 6.4.1. Centralized Manufacturing
  • 6.4.2. Decentralized Manufacturing
• 6.5. Scalability of Cell Therapy Manufacturing Processes
  • 6.5.1. Scale-up
  • 6.5.2. Scale-out
• 6.6. Types of Cell Therapy Manufacturers
• 6.7. Key Challenges for Manufacturing Cell Therapies
• 6.8. Key Factors Influencing Cell Therapy Manufacturing
  • 6.8.1. Cell Characterization
  • 6.8.2. Cost of Goods
• 6.9. Automation of Cell Therapy Manufacturing
• 6.10. Cell Therapy Manufacturing Supply Chain
• 6.11. Future Perspectives

7. CELL THERAPY MANUFACTURERS (INDUSTRY PLAYERS): MARKET LANDSCAPE

• 7.1. Chapter Overview
• 7.2. Industry Players: Overall Market Landscape
  • 7.2.1. Analysis by Year of Establishment
  • 7.2.2. Analysis by Company Size
  • 7.2.3. Analysis by Location of Headquarters (Region)
  • 7.2.4. Analysis by Location of Headquarters (Country)
  • 7.2.5. Analysis by Company Size and Location of Headquarters (Region)
  • 7.2.6. Analysis by Location of Manufacturing Facility
  • 7.2.7. Analysis by Type of Immune Cell Offered
  • 7.2.8. Analysis by Source of Cells
  • 7.2.9. Analysis by Scale of Operation
  • 7.2.10. Analysis by Type of Additional Service Offered

8. CELL THERAPY MANUFACTURERS (NON-INDUSTRY PLAYERS): MARKET LANDSCAPE

• 8.1. Chapter Overview
• 8.2. Non-Industry Players: Overall Market Landscape
  • 8.2.1. Analysis by Year of Establishment
  • 8.2.2. Analysis by Location of Headquarters (Region)
  • 8.2.3. Analysis by Location of Headquarters (Country)
  • 8.2.4. Analysis by Location of Manufacturing Facility
  • 8.2.5. Analysis by Type of Immune Cell Offered
  • 8.2.6. Analysis by Source of Cell
  • 8.2.7. Analysis by Scale of Operation
  • 8.2.8. Analysis by Type of Additional Service Offered

9. REGULATORY LANDSCAPE

• 9.1. Chapter Overview
• 9.2. Current Scenario
  • 9.2.1. Regulatory Guidelines in North America
  • 9.2.2. Regulatory Guidelines in Europe
  • 9.2.3. Regulatory Guidelines in Asia-Pacific
    • 9.2.3.1. Regulatory Guidelines in Japan
    • 9.2.3.2. Regulatory Guidelines in China
  • 9.2.4. Conditional Approvals
• 9.3. Regulatory Authorities for Cell Therapy Manufacturing
  • 9.3.1. Cell Therapy Manufacturing (Industry Players): Regulatory Authorities
• 9.4. Summary of Guidelines for Early-Stage Manufacturing of Cell Therapies
• 9.5. Existing Challenges to Early-Stage Manufacturing of Cell Therapies
• 9.6. Variability in Regulatory Guidelines across Different Geographies

10. CASE STUDY: ROADMAPS FOR OVERCOMING CHALLENGES RELATED TO CELL THERAPY MANUFACTURING

• 10.1. Chapter Overview
• 10.2. Roadmap for the US
  • 10.2.1. Cell Processing
  • 10.2.2. Cell Preservation, Distribution and Handling
  • 10.2.3. Process Automation and Data Analytics
  • 10.2.4. Process Monitoring and Quality Control
  • 10.2.5. Standardization and Regulatory Support
  • 10.2.6. Workforce Development
  • 10.2.7. Supply Chain and Logistics
• 10.3. Roadmaps for Other Geographies
  • 10.3.1. Europe
  • 10.3.2. Asia-Pacific

11. CASE STUDY: AUTOMATION TECHNOLOGIES FOR CELL THERAPY MANUFACTURING

• 11.1. Chapter Overview
• 11.2. Automation of Cell Therapy Manufacturing Processes
  • 11.2.1. Closed Systems
  • 11.2.2. Single-use Systems
  • 11.2.3. Modular Systems
• 11.3. Growth Drivers and Roadblocks
• 11.4. Case Studies
  • 11.4.1. Roadmap to Develop an Automated Cell Manufacturing / Processing Device
  • 11.4.2. Automating the Cell Therapy Manufacturing Process
  • 11.4.3. Advancement to Automation of Cell Therapy Manufacturing Process
  • 11.4.4. GMP-in-a-Box
  • 11.4.5. List of Automated and Closed Cell Therapy Processing Systems

12. COMPANY PROFILES: INDUSTRY PLAYERS

• 12.1. Chapter Overview
• 12.2. Service Providers in North America
  • 12.2.1. Advanced Therapies
    • 12.2.1.1. Company Overview
    • 12.2.1.2. Financial Information
    • 12.2.1.3. Service Portfolio
    • 12.2.1.4. Manufacturing Facilities and Capabilities
    • 12.2.1.5. Recent Developments and Future Outlook
• similar details are presented for other below mentioned players based on information in the public domain
  • 12.2.2. AGC Biologics
  • 12.2.3. Catalent
  • 12.2.4. Charles River Laboratories
  • 12.2.5. ImmunityBio
  • 12.2.6. Merck Millipore
  • 12.2.7. Minaris Advanced Therapies
  • 12.2.8. Resilience
  • 12.2.9. SK pharmteco (Subsidiary of SK Inc.)
  • 12.2.10. Thermo Fisher Scientific
• 12.3. Service Providers in Europe
  • 12.3.1. Evotec
  • 12.3.2. Lonza
  • 12.3.3. Miltenyi Biotec
  • 12.3.4. Sartorius
• 12.4. Service Providers in Asia-Pacific
  • 12.4.1. Astellas Pharma
  • 12.4.2. OBiO Tech
  • 12.4.3. Pharmaron
  • 12.4.4. Takara Bio

13. COMPANY PROFILES: NON-INDUSTRY PLAYERS

• 13.1. Chapter Overview
• 13.2. City of Hope
  • 13.2.1. Overview
  • 13.2.2. Service Portfolio
  • 13.2.3. Type of Additional Service Offered
• similar details are presented for other below mentioned players based on information in the public domain
• 13.3. Clinical Cell and Vaccine Production Facility (CVPF)
• 13.4. Fraunhofer Institute for Cell Therapy and Immunology
• 13.5. Newcastle Advanced Therapies
• 13.6. NHS Blood and Transplant
• 13.7. Rayne Cell Therapy Suite (King's College London)
• 13.8. Scottish National Blood Transfusion Service (SNBTS) Cellular Therapy Facility

14. NON-PROFIT ORGANIZATIONS IN CELL THERAPY MANUFACTURING

• 14.1. Chapter Overview
• 14.2. Cell Therapy Manufacturing: Non-Profit Organizations
  • 14.2.1. CellCAN
  • 14.2.2. Cell Therapy Manufacturing Cooperative Research Center
  • 14.2.3. National Cell Manufacturing Consortium (NCMC)
  • 14.2.4. California Institute of Regenerative Medicine (CIRM)
• 14.3. Cell Therapy Manufacturing: International Societies

15. CLINICAL TRIAL ANALYSIS

• 15.1. Chapter Overview
• 15.2. Scope and Methodology
• 15.3. Cell Therapies: Clinical Trial Analysis
  • 15.3.1. Analysis by Trial Registration Year
  • 15.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
  • 15.3.3. Analysis by Trial Status
  • 15.3.4. Analysis by Trial Registration Year and Trial Status
  • 15.3.5. Analysis by Trial Phase
  • 15.3.6. Analysis of Enrolled Patient Population by Trial Phase
  • 15.3.7. Analysis by Patient Gender
  • 15.3.8. Analysis by Study Design
    • 15.3.8.1. Analysis by Type of Allocation
    • 15.3.8.2. Analysis by Intervention Model
    • 15.3.8.3. Analysis by Type of Masking
  • 15.3.9. Analysis by Type of Sponsor / Collaborator
  • 15.3.10. Most Active Players: Analysis by Number of Registered Trials
  • 15.3.11. Analysis by Geography
    • 15.3.11.1. Analysis of Clinical Trials by Geography
    • 15.3.11.2. Analysis of Clinical Trials by Trial Status and Geography
    • 15.3.11.3. Analysis of Enrolled Patient Population by Trial Status and Geography

16. PARTNERSHIPS AND COLLABORATIONS

• 16.1. Chapter Overview
• 16.2. Partnership Models
• 16.3. Cell Therapy Manufacturing: List of Partnerships
  • 16.3.1. Analysis by Year of Partnership
  • 16.3.2. Analysis by Type of Partnership
  • 16.3.3. Analysis by Year and Type of Partnership
• 16.4. Analysis by Type of Immune Cell Offered
• 16.5. Analysis by Scale of Operation
• 16.6. Most Active Players: Analysis by Number of Partnerships
• 16.7. Analysis by Geography
  • 16.7.1. Local and International Agreements
  • 16.7.2. Intracontinental and Intercontinental Agreements

17. RECENT EXPANSIONS

• 17.1. Chapter Overview
• 17.2. Type of Expansions
• 17.3. Cell Therapy Manufacturing: Recent Expansions
  • 17.3.1. Analysis by Year of Expansion
  • 17.3.2. Analysis by Type of Expansion
  • 17.3.3. Analysis by Year and Type of Expansion
  • 17.3.4. Analysis by Location of Expanded Facility (Region)
  • 17.3.5. Analysis by Location of Expanded Facility (Country)
  • 17.3.6. Analysis by Type of Expansion and Location of Headquarters (Country)
  • 17.3.7. Analysis by Type of Immune Cell Offered
  • 17.3.8. Analysis by Type of Expansion and Type of Immune Cell Offered
  • 17.3.9. Analysis by Scale of Operation
  • 17.3.10. Most Active Players: Analysis by Number of Expansions
  • 17.3.11. Most Active Players: Analysis by Area of Expansion

18. BIG PHARMA INITIATIVES

• 18.1. Chapter Overview
• 18.2. Cell Therapy Manufacturing: List of Big Pharma Players
• 18.3. Cell Therapy Manufacturing: List of Initiatives by Big Pharma Players
  • 18.3.1. Analysis by Year of Initiative
  • 18.3.2. Analysis by Type of Initiative
  • 18.3.3. Analysis by Year and Type of Initiative
  • 18.3.4. Big Players: Analysis by Number of Initiatives
  • 18.3.5. Analysis by Type of Partnership
  • 18.3.6. Big Players: Analysis by Number of Partnerships
  • 18.3.7. Analysis by Type of Facility Expansion
  • 18.3.8. Big Players: Analysis by Number of Facility Expansions
  • 18.3.9. Big Players: Analysis by Region of Facility Expansion
  • 18.3.10. Big Players: Analysis by Number of Mergers and Acquisitions
  • 18.3.11. Big Players: Analysis by Number of Funding and Investment
  • 18.3.12. Analysis by Type of Immune Cell Offered
  • 18.3.13. Analysis by Scale of Operation
  • 18.3.14. Analysis of Big Pharma Players by Scale of Operation
  • 18.3.15. Big Pharma Initiatives Summary

19. CAPACITY ANALYSIS

• 19.1. Chapter Overview
• 19.2. Industry Players: Key Assumptions and Methodology
  • 19.2.1. Cell Therapy Manufacturing: Global Installed Capacity (Number of Cleanrooms)
    • 19.2.1.1. Analysis by Company Size
    • 19.2.1.2. Analysis by Scale of Operation
    • 19.2.1.3. Analysis by Location of Manufacturing Facility
    • 19.2.1.4. Analysis by Company Size and Location of Manufacturing Facility
    • 19.2.1.5. Analysis by Scale of Operation and Location of Manufacturing Facility
  • 19.2.2. Cell Therapy Manufacturing: Global Installed Capacity (Cleanroom Area)
    • 19.2.2.1. Analysis by Company Size
    • 19.2.2.2. Analysis by Scale of Operation
    • 19.2.2.3. Analysis by Location of Manufacturing Facility
    • 19.2.2.4. Analysis by Company Size and Location of Manufacturing Facility
    • 19.2.2.5. Analysis by Scale of Operation and Location of Manufacturing Facility
• 19.3. Non- Industry Players: Key Assumptions and Methodology
  • 19.3.1. Cell Therapy Manufacturing: Global Installed Capacity (Number of Cleanrooms)
    • 19.3.1.1. Analysis by Scale of Operation
    • 19.3.1.2. Analysis by Location of Manufacturing Facility
  • 19.3.2. Cell Therapy Manufacturing: Global Installed Capacity (Cleanroom Area)
    • 19.3.2.1. Analysis by Scale of Operation
    • 19.3.2.2. Analysis by Location of Manufacturing Facility
• 19.4. Concluding Remarks

20. DEMAND ANALYSIS

• 20.1. Chapter Overview
• 20.2. Assumptions and Methodology
• 20.3. Global Demand for Cell Therapy Manufacturing
• 20.4. Global Clinical Demand for Cell Therapy Manufacturing
  • 20.4.1. Clinical Demand: Analysis by Type of Cell Therapy
  • 20.4.2. Clinical Demand: Analysis by Geography
• 20.5. Global Commercial Demand for Cell Therapy Manufacturing
  • 20.5.1. Commercial Demand: Analysis by Type of Cell Therapy
  • 20.5.2. Commercial Demand: Analysis by Geography

21. COST PRICE ANALYSIS

• 21.1. Chapter Overview
• 21.2. Factors Contributing to the High Price of Cell Therapies
• 21.3. Pricing Models for Cell Therapies
  • 21.3.1. Based on Associated Costs for T-cell Therapies
  • 21.3.2. Based on Associated Costs for Stem Cell Therapies
  • 21.3.3. Based on Availability of Competing Products
  • 21.3.4. Based on Target Patient Segment
  • 21.3.5. Based on the Opinions of Industry Experts
• 21.4. Cell Therapy Cost Optimization
  • 21.4.1. Role of Cost of Goods Sold
  • 21.4.2. Role of Automation
• 21.5. Role of Cell Therapy Contract Manufacturing Organizations
• 21.6. Reimbursement-related Considerations for Cell Therapies
  • 21.6.1. Case Study: The National Institute for Health and Care Excellence's (NICE) Appraisal of CAR-T Therapies

22. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

• 22.1. Chapter Overview
• 22.2. Assumptions and Key Parameters
• 22.3. Cell Therapy Manufacturing: Make versus Buy Decision Making
  • 22.3.1. Scenario 1
  • 22.3.2. Scenario 2
  • 22.3.3. Scenario 3
  • 22.3.4. Scenario 4

23. TOTAL COST OF OWNERSHIP FOR CELL THERAPY MANUFACTURING ORGANIZATIONS

• 23.1. Chapter Overview
• 23.2. Key Parameters
• 23.3. Assumptions and Methodology
• 23.4. Sample Dataset for the Estimation of Total Cost of Ownership
• 23.5. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0-Y20
• 23.6. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Analysis by CAPEX and OPEX, Y0 and Y20
  • 23.6.1. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Analysis by CAPEX, Y0
  • 23.6.2. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Analysis by OPEX, Y1-Y20

24. SWOT ANALYSIS

• 24.1. Chapter Overview
• 24.2. Strengths
• 24.3. Weaknesses
• 24.4. Opportunities
• 24.5. Threats
• 24.6. Comparison of SWOT Factors

25. SURVEY ANALYSIS

• 25.1. Chapter Overview
• 25.2. Analysis by Designation of Respondents
• 25.3. Analysis by Type of Cell Therapy
• 25.4. Analysis by Scale of Operation
• 25.5. Analysis by Source of Cells
• 25.6. Analysis by Type of Cell Culture System Used
• 25.7. Analysis by Availability of Fill / Finish Services

26. GLOBAL CELL THERAPY MANUFACTURING MARKET

• 26.1. Chapter Overview
• 26.2. Assumptions and Methodology
• 26.3. Global Cell Therapy Manufacturing Market, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
• 26.4. Roots Analysis Perspective on Market Growth
• 26.5. Scenario Analysis
  • 26.5.1. Conservative Scenario
  • 26.5.2. Optimistic Scenario
• 26.6. Key Market Segmentations

27. CELL THERAPY MANUFACTURING MARKET, BY TYPE OF CELL THERAPY

• 27.1. Chapter Overview
• 27.2. Key Assumptions and Methodology
• 27.3. Cell Therapy Manufacturing Market: Distribution by Type of Cell Therapy
  • 27.3.1. Cell Therapy Manufacturing Market for CAR-T Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 27.3.2. Cell Therapy Manufacturing Market for Stem Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 27.3.3. Cell Therapy Manufacturing Market for TCR Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 27.3.4. Cell Therapy Manufacturing Market for TIL Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 27.3.5. Cell Therapy Manufacturing Market for Dendritic Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 27.3.6. Cell Therapy Manufacturing Market for Other Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
• 27.4. Data Triangulation and Validation

28. CELL THERAPY MANUFACTURING MARKET, BY SOURCE OF CELLS

• 28.1. Chapter Overview
• 28.2. Key Assumptions and Methodology
• 28.3. Cell Therapy Manufacturing Market: Distribution by Source of Cells
  • 28.3.1. Cell Therapy Manufacturing Market for Autologous Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 28.3.2. Cell Therapy Manufacturing Market for Allogeneic Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 28.3.3. Cell Therapy Manufacturing Market for Other Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
• 28.4. Data Triangulation and Validation

29. CELL THERAPY MANUFACTURING MARKET, BY SCALE OF OPERATION

• 29.1. Chapter Overview
• 29.2. Key Assumptions and Methodology
• 29.3. Cell Therapy Manufacturing Market: Distribution by Scale of Operation
  • 29.3.1. Cell Therapy Manufacturing Market for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 29.3.2. Cell Therapy Manufacturing Market for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)

30. CELL THERAPY MANUFACTURING MARKET, BY TYPE OF MANUFACTURER

• 30.1. Chapter Overview
• 30.2. Key Assumptions and Methodology
• 30.3. Cell Therapy Manufacturing Market: Distribution by Type of Manufacturer
  • 30.3.1. Cell Therapy Manufacturing Market for Contract Manufacturing Organizations, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 30.3.2. Cell Therapy Manufacturing Market for In-House Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
• 30.4. Data Triangulation and Validation

31. CELL THERAPY MANUFACTURING MARKET, BY GEOGRAPHY

• 31.1. Chapter Overview
• 31.2. Key Assumptions and Methodology
• 31.3. Cell Therapy Manufacturing Market: Distribution by Geography
  • 31.3.1. Clinical Cell Therapy Manufacturing Market
    • 31.3.1.1. Clinical Cell Therapy Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 31.3.1.1.1. Clinical Cell Therapy Manufacturing Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 31.3.1.1.2. Clinical Cell Therapy Manufacturing Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    • 31.3.1.2. Clinical Cell Therapy Manufacturing Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 31.3.1.2.1. Clinical Cell Therapy Manufacturing Market in Spain, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 31.3.1.2.2. Clinical Cell Therapy Manufacturing Market in France, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 31.3.1.2.3. Clinical Cell Therapy Manufacturing Market in Germany, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 31.3.1.2.4. Clinical Cell Therapy Manufacturing Market in the UK, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 31.3.1.2.5. Clinical Cell Therapy Manufacturing Market in Italy, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    • 31.3.1.3. Clinical Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 31.3.1.3.1. Clinical Cell Therapy Manufacturing Market in China, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 31.3.1.3.2. Clinical Cell Therapy Manufacturing Market in Singapore, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 31.3.1.3.3. Clinical Cell Therapy Manufacturing Market in South Korea, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 31.3.1.3.4. Clinical Cell Therapy Manufacturing Market in Israel, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 31.3.1.3.5. Clinical Cell Therapy Manufacturing Market in Japan, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 31.3.1.3.6. Clinical Cell Therapy Manufacturing Market in Taiwan, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 31.3.1.3.7. Clinical Cell Therapy Manufacturing Market in Brazil, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 31.3.1.3.8. Clinical Cell Therapy Manufacturing Market in Argentina, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 31.3.1.3.9. Clinical Cell Therapy Manufacturing Market in South Africa, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  • 31.3.2. Commercial Cell Therapy Manufacturing Market
    • 31.3.2.1. Commercial Cell Therapy Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 31.3.2.1.1. Commercial Cell Therapy Manufacturing Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 31.3.2.1.2. Commercial Cell Therapy Manufacturing Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    • 31.3.2.2. Commercial Cell Therapy Manufacturing Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 31.3.2.2.1. Commercial Cell Therapy Manufacturing Market in Germany, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 31.3.2.2.2. Commercial Cell Therapy Manufacturing Market in France, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 31.3.2.2.3. Commercial Cell Therapy Manufacturing Market in the UK, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 31.3.2.2.4. Commercial Cell Therapy Manufacturing Market in Italy, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 31.3.2.2.5. Commercial Cell Therapy Manufacturing Market in Spain, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 31.3.2.2.6. Commercial Cell Therapy Manufacturing Market in Rest of Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    • 31.3.2.3. Commercial Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 31.3.2.3.1. Commercial Cell Therapy Manufacturing Market in China, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 31.3.2.3.2. Commercial Cell Therapy Manufacturing Market in Japan, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 31.3.2.3.3. Commercial Cell Therapy Manufacturing Market in Australia, Historical Trends (since 2023) and Forecasted Estimates (2025-2035)
      • 31.3.2.3.4. Commercial Cell Therapy Manufacturing Market in India, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 31.3.2.3.5. Commercial Cell Therapy Manufacturing Market in South Korea, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
      • 31.3.2.3.6. Commercial Cell Therapy Manufacturing Market in Brazil, Historical Trends (since 2024) and Forecasted Estimates (till 2035)
• 31.4. Penetration Growth (P-G) Matrix
• 31.5. Market Dynamics Assessment

32. CELL THERAPY MANUFACTURING MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

• 32.1. Cell Therapy Manufacturing Market in North America: Distribution by Type of Cell therapy
  • 32.1.1. Cell Therapy Manufacturing Market in North America for CAR-T Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  • 32.1.2. Cell Therapy Manufacturing Market in North America for Stem Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  • 32.1.3. Cell Therapy Manufacturing Market in North America for TCR Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  • 32.1.4. Cell Therapy Manufacturing Market in North America for TIL Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  • 32.1.5. Cell Therapy Manufacturing Market in North America for Dendritic Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  • 32.1.6. Cell Therapy Manufacturing Market in North America for Other Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
• 32.2. Cell Therapy Manufacturing Market in North America: Distribution by Source of Cells
  • 32.2.1. Cell Therapy Manufacturing Market in North America for Autologous Cells, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  • 32.2.2. Cell Therapy Manufacturing Market in North America for Allogeneic Cells, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  • 32.2.3. Cell Therapy Manufacturing Market in North America for Other Cells, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
• 32.3. Cell Therapy Manufacturing Market in North America: Distribution by Scale of Operation
  • 32.3.1. Cell Therapy Manufacturing Market in North America for Clinical Scale, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  • 32.3.2. Cell Therapy Manufacturing Market in North America for Commercial Scale, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
• 32.4. Cell Therapy Manufacturing Market in North America: Distribution by Type of Manufacturer
  • 32.4.1. Cell Therapy Manufacturing Market in North America for Contract Manufacturing Organizations, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  • 32.4.2. Cell Therapy Manufacturing Market in North America for In-House Manufacturers, Historical Trends (since 2022) and Forecasted Estimates (till 2035)

33. CELL THERAPY MANUFACTURING MARKET OPPORTUNITY ANALYSIS: EUROPE

• 33.1. Cell Therapy Manufacturing Market in Europe: Distribution by Type of Cell therapy
  • 33.1.1. Cell Therapy Manufacturing Market in Europe for CAR-T Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  • 33.1.2. Cell Therapy Manufacturing Market in Europe for Stem Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  • 33.1.3. Cell Therapy Manufacturing Market in Europe for TCR Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  • 33.1.4. Cell Therapy Manufacturing Market in Europe for TIL Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  • 33.1.5. Cell Therapy Manufacturing Market in Europe for Dendritic Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  • 33.1.6. Cell Therapy Manufacturing Market in Europe for Other Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
• 33.2. Cell Therapy Manufacturing Market in Europe: Distribution by Source of Cells
  • 33.2.1. Cell Therapy Manufacturing Market in Europe for Autologous Cells, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  • 33.2.2. Cell Therapy Manufacturing Market in Europe for Allogeneic Cells, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  • 33.2.3. Cell Therapy Manufacturing Market in Europe for Other Cells, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
• 33.3. Cell Therapy Manufacturing Market in Europe: Distribution by Scale of Operation
  • 33.3.1. Cell Therapy Manufacturing Market in Europe for Clinical Scale, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  • 33.3.2. Cell Therapy Manufacturing Market in Europe for Commercial Scale, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
• 33.4. Cell Therapy Manufacturing Market in Europe: Distribution by Type of Manufacturer
  • 33.4.1. Cell Therapy Manufacturing Market in Europe for Contract Manufacturing Organizations, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  • 33.4.2. Cell Therapy Manufacturing Market in Europe for In-House Manufacturers, Historical Trends (since 2022) and Forecasted Estimates (till 2035)

34. CELL THERAPY MANUFACTURING MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC AND REST OF THE WORLD

• 34.1. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Type of Cell therapy
  • 34.1.1. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for CAR-T Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  • 34.1.2. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Stem Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  • 34.1.3. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for TCR Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  • 34.1.4. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for TIL Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  • 34.1.5. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Dendritic Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  • 34.1.6. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Other Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
• 34.2. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Source of Cells
  • 34.2.1. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Autologous Cells, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  • 34.2.2. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Allogeneic Cells, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  • 34.2.3. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Other Cells, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
• 34.3. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Scale of Operation
  • 34.3.1. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Clinical Scale, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  • 34.3.2. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Commercial Scale, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
• 34.4. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Type of Manufacturer
  • 34.4.1. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Contract Manufacturing Organizations, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  • 34.4.2. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for In-House Manufacturers, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
• *Detailed information on Chapters 32-34 is available in the Excel Data Packs shared along with the report**

35. CONCLUDING REMARKS

36. EXECUTIVE INSIGHTS

• 36.1. Chapter Overview
• 36.2. Company A (Mid-sized Company, Australia)
  • 36.2.1. Company Snapshot
  • 36.2.2. Interview Transcript: Marketing Manager, Cell Therapy
• 36.3. Company B (UK)
  • 36.3.1. Company Snapshot
  • 36.3.2. Interview Transcript: Director
• 36.4. Company C (Small Company, Belgium)
  • 36.4.1. Company Snapshot
  • 36.4.2. Interview Transcript: Marketing Director
• 36.5. Company D (Large Company, Poland)
  • 36.5.1. Company Snapshot
  • 36.5.2. Interview Transcript: Management Board Vice-President
• 36.6. Company E (Small Company, US)
  • 36.6.1. Company Snapshot
  • 36.6.2. Interview Transcript: Senior Director of Sales Advanced Therapies; Vice President of Marketing
• 36.7. Company F (Mid-sized Company, Japan)
  • 36.7.1. Company Snapshot
  • 36.7.2. Interview Transcript: Business Administration Department Manager
• 36.8. Company G (Small Company, Netherlands)
  • 36.8.1. Company Snapshot
  • 36.8.2. Interview Transcript: Chief Business Officer
• 36.9. Company H (US)
  • 36.9.1. Company Snapshot
  • 36.9.2. Interview Transcript: Director of Finance and Facility Operations
• 36.10. Company I (Very Large Company, Japan)
  • 36.10.1. Company Snapshot
  • 36.10.2. Interview Transcript: Senior Director
• 36.11. Company J (Mid-sized Company, UK)
  • 36.11.1. Company Snapshot
  • 36.11.2. Interview Transcript: Chief Executive Officer
• 36.12. Company K (Large Company, US)
  • 36.12.1. Company Snapshot
  • 36.12.2. Interview Transcript: Former Chief Technical Officer
• 36.13. Company L (Small Company, Netherlands)
  • 36.13.1. Company Snapshot
  • 36.13.2. Interview Transcript: Former Chief Executive Officer,
• 36.14. Company M (Small Company, France)
  • 36.14.1. Company Snapshot
  • 36.14.2. Interview Transcript: Former General Manager
• 36.15. Company N (Large Company, China)
  • 36.15.1. Company Snapshot
  • 36.15.2. Interview Transcript: Chief Executive Officer
• 36.16. Company O (Small Company, Israel)
  • 36.16.1. Company Snapshot
  • 36.16.2. Interview Transcript: Executive Vice President Research and Development
• 36.17. Company P (Mid-sized Company, UK)
  • 36.17.1. Company Snapshot
  • 36.17.2. Interview Transcript: Former Business Development Manager
• 36.18. Company Q (US)
  • 36.18.1. Company Snapshot
  • 36.18.2. Interview Transcript: Professor and American Red Cross Chair in Transfusion Medicine
• 36.19. Company R (Small Company, Singapore)
  • 36.19.1. Company Snapshot
  • 36.19.2. Interview Transcript: Former Co-Founder and Chief Executive Officer
• 36.20. Company S (Mid-sized Company, Canada)
  • 36.20.1. Company Snapshot
  • 36.20.2. Interview Transcript: Former Manager, Business Development and Operations-cGMP Manufacturing Unit
• 36.21. Company T (Small Company, US)
  • 36.21.1. Company Snapshot
  • 36.21.2. Interview Transcript: Manager of Business Development
• 36.22. Company U (Mid-sized Company, France)
  • 36.22.1. Company Snapshot
  • 36.22.2. Interview Transcript: Former Department Leader, Cell Therapy Innovation and Development
• 36.23. Company V (Mid-sized Company, Australia)
  • 36.23.1. Company Snapshot
  • 36.23.2. Interview Transcript: Former Chief Executive Officer
• 36.24. Company W (Small Company, Netherlands)
  • 36.24.1. Company Snapshot
  • 36.24.2. Interview Transcript: Chief Executive Officer

37. APPENDIX I: TABULATED DATA

38. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

• Table 6.1 Cell-based Therapies: Applications
• Table 6.2 Differences between Cell Therapy and Biotechnological Products
• Table 6.3 Cell-based Therapies: Commercialized Products
• Table 6.4 Assessment of Cell Therapy Manufacturing Steps
• Table 6.5 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
• Table 7.1 Industry Players: Information on Year of Establishment, Company Size, Location of Headquarters, Number of Manufacturing Facilities and Location of Manufacturing Facility
• Table 7.2 Industry Players: Information on Type of Immune Cell Offered
• Table 7.3 Industry Players: Information on Source of Cells and Scale of Operation
• Table 7.4 Industry Players: Information on Type of Additional Service Offered
• Table 8.1 Non-Industry Players: Information on Year of Establishment, Location of Headquarters, Number of Manufacturing Facilities and Location of Manufacturing Facility
• Table 8.2 Non-Industry Players: Information on Type of Immune Cell Offered
• Table 8.3 Non-Industry Players: Information on Source of Cell and Scale of Operation
• Table 8.4 Non-Industry Players: Information on Type of Additional Service Offered
• Table 9.1 Cell Therapy Manufacturing (Industry Players): Regulatory Authorities
• Table 9.2 Cell Therapy Manufacturing (Non-Industry Players): Regulatory Authorities
• Table 9.3 Summary of Guidelines for Early-Stage Manufacturing of Cell Therapies
• Table 10.1 Cell Therapy Manufacturing: Roadmap for the US
• Table 10.2 Cell Processing: Challenges and Strategies
• Table 10.3 Cell Preservation, Distribution and Handling: Challenges and Strategies
• Table 10.4 Process Monitoring and Quality Control: Challenges and Strategies
• Table 10.5 Standardization and Regulatory Support: Challenges and Strategies
• Table 10.6 Workforce Development: Challenges and Strategies
• Table 10.7 Supply Chain and Logistics: Challenges and Strategies
• Table 10.8 Cell Therapy Manufacturing: Roadmap for the Asia Pacific Economic Cooperation (APEC)
• Table 11.1 Cell Therapy Manufacturing: List of Automated and Closed Cell Therapy Processing Systems
• Table 12.1 Cell Therapy Manufacturing Industry Players: List of Companies Profiled
• Table 12.2 Advanced Therapies: Company Snapshot
• Table 12.3 Advanced Therapies: Information on Manufacturing Facilities and Capabilities
• Table 12.4 Advanced Therapies: Recent Developments and Future Outlook
• Table 12.5 AGC Biologics: Company Snapshot
• Table 12.6 AGC Biologics: Information on Manufacturing Facilities and Capabilities
• Table 12.7 AGC Biologics: Recent Developments and Future Outlook
• Table 12.8 Catalent: Company Snapshot
• Table 12.9 Catalent: Information on Manufacturing Facilities and Capabilities
• Table 12.10 Catalent: Recent Developments and Future Outlook
• Table 12.11 Charles River Laboratories: Company Snapshot
• Table 12.12 Charles River Laboratories: Information on Manufacturing Facilities and Capabilities
• Table 12.13 Charles River Laboratories: Recent Developments and Future Outlook
• Table 12.14 ImmunityBio: Company Snapshot
• Table 12.15 ImmunityBio: Information on Manufacturing Facilities and Capabilities
• Table 12.16 ImmunityBio: Recent Developments and Future Outlook
• Table 12.17 Merck Millipore: Company Snapshot
• Table 12.18 Merck Millipore: Information on Manufacturing Facilities and Capabilities
• Table 12.19 Merck Millipore: Recent Developments and Future Outlook
• Table 12.20 Minaris Advanced Therapies: Company Snapshot
• Table 12.21 Minaris Advanced Therapies: Information on Manufacturing Facilities and Capabilities
• Table 12.22 Minaris Advanced Therapies: Recent Developments and Future Outlook
• Table 12.23 Resilience: Company Snapshot
• Table 12.24 Resilience: Information on Manufacturing Facilities and Capabilities
• Table 12.25 Resilience: Recent Developments and Future Outlook
• Table 12.26 SK pharmteco (Subsidiary of SK Inc.): Company Snapshot
• Table 12.27 SK pharmteco (Subsidiary of SK Inc.): Information on Manufacturing Facilities and Capabilities
• Table 12.28 SK pharmteco (Subsidiary of SK Inc.): Recent Developments and Future Outlook
• Table 12.29 Thermo Fisher Scientific: Company Snapshot
• Table 12.30 Thermo Fisher Scientific: Information on Manufacturing Facilities and Capabilities
• Table 12.31 Thermo Fisher Scientific: Recent Developments and Future Outlook
• Table 13.1 Cell Therapy Manufacturing (Non-Industry Players): List of Organizations Profiled
• Table 13.2 City of Hope: Overview
• Table 13.3 City of Hope: Service Portfolio
• Table 13.4 Clinical Cell and Vaccine Production Facility (CVPF): Overview
• Table 13.5 Clinical Cell and Vaccine Production Facility (CVPF): Service Portfolio
• Table 13.6 Fraunhofer Institute for Cell Therapy and Immunology: Overview
• Table 13.7 Fraunhofer Institute for Cell Therapy and Immunology: Service Portfolio
• Table 13.8 Newcastle Advanced Therapies: Overview
• Table 13.9 Newcastle Advanced Therapies: Service Portfolio
• Table 13.10 NHS Blood and Transplant: Overview
• Table 13.11 NHS Blood and Transplant: Service Portfolio
• Table 13.12 Rayne Cell Therapy Suite (King's College London): Overview
• Table 13.13 Rayne Cell Therapy Suite (King's College London): Service Portfolio
• Table 13.14 Scottish National Blood Transfusion Service (SNBTS) Cellular Therapy Facility: Overview
• Table 13.15 Scottish National Blood Transfusion Service (SNBTS) Cellular Therapy Facility: Service Portfolio
• Table 14.1 Cell Therapy Manufacturing: List of Non-Profit Organizations
• Table 14.2 CellCAN: Overview
• Table 14.3 Cell Therapy Manufacturing Cooperative Research Center: Overview
• Table 14.4 National Cell Manufacturing Consortium: Overview
• Table 14.5 California's Institute of Regenerative Medicine: Overview
• Table 16.1 Cell Therapy Manufacturing: List of Partnerships and Collaborations
• Table 16.2 Partnerships and Collaborations: Information on Type of Immune Cell Offered and Scale of Operation
• Table 16.3 Partnerships and Collaborations: Information on Location of Headquarters (Country and Region) and Type of Agreement (Country and Region)
• Table 17.1 Cell Therapy Manufacturing: List of Expansions
• Table 17.2 Cell Therapy Manufacturing: Type of Immune Cell Offered and Scale of Operation
• Table 18.1 List of Top 10 Big Pharma Players
• Table 18.2 Big Pharma Players: List of Cell Therapy Manufacturing Focused Initiatives, Since 2021
• Table 18.3 Big Pharma Initiatives: Information on Type of Immune Cell Offered and Scale of Operation
• Table 19.1 Average Installed Cell Therapy Manufacturing Capacity (Number of Cleanrooms): Sample Data Set for Industry Players
• Table 19.2 Average Installed Cell Therapy Manufacturing Capacity (Cleanroom Area): Sample Data Set for Industry Players
• Table 19.3 Global Installed capacity of industry players for cell therapy manufacturing (Number of Cleanrooms): Distribution by Company Size
• Table 19.4 Global Installed capacity of industry players for cell therapy manufacturing (Cleanroom Area): Distribution by Company Size
• Table 19.5 Median Installed Cell Therapy Manufacturing Capacity (Number of Cleanrooms): Data Set for Non-Industry Players
• Table 19.6 Median Installed Cell Therapy Manufacturing Capacity (Cleanroom Area): Dat Set for Non-Industry Players
• Table 21.1 Costs Associated with Manufacturing Stem Cell Therapies
• Table 21.2 Pricing Model: Price of Marketed Drugs (Antibody Drug Conjugates and Monoclonal Antibodies)
• Table 21.3 T-cell Immunotherapies: Expert Opinions on Pricing
• Table 21.4 CAR-T Cell Therapies: Reimbursement Landscape
• Table 23.1 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0-Y20 (USD Million)
• Table 23.2 Total Cost of Ownership: Sample Dataset
• Table 25.1 Survey Insights: Overview of Respondents
• Table 25.2 Survey Insights: Designations and Seniority Levels
• Table 25.3 Survey Insights: Type of Cell Therapy
• Table 25.4 Survey Insights: Scale of Operation
• Table 25.5 Survey Insights: Source of Cells
• Table 25.6 Survey Insights: Cell Culture System
• Table 25.7 Survey Insights: Availability of Fill / Finish Services
• Table 37.1 Industry Players: Distribution by Year of Establishment
• Table 37.2 Industry Players: Distribution by Company Size
• Table 37.3 Industry Players: Distribution by Location of Headquarters (Region)
• Table 37.4 Industry Players: Distribution by Location of Headquarters (Country)
• Table 37.5 Industry Players: Distribution by Company Size and Location of Headquarters (Region)
• Table 37.6 Industry Players: Distribution by Location of Manufacturing Facility (Region)
• Table 37.7 Industry Players: Distribution by Location of Manufacturing Facility (Country)
• Table 37.8 Industry Players: Distribution by Type of Immune Cell Offered
• Table 37.9 Industry Players: Distribution by Source of Cells
• Table 37.10 Industry Players: Distribution by Scale of Operation
• Table 37.11 Industry Players: Distribution by Type of Additional Service Offered
• Table 37.12 Non-Industry Players: Distribution by Year of Establishment
• Table 37.13 Non-Industry Players: Distribution by Location of Headquarters (Region)
• Table 37.14 Non-Industry Players: Distribution by Location of Headquarters (Country)
• Table 37.15 Non-Industry Players: Distribution by Location of Manufacturing Facility (Region)
• Table 37.16 Non-Industry Players: Distribution by Location of Manufacturing Facility (Country)
• Table 37.17 Non-Industry Players: Distribution by Type of Immune Cell Offered
• Table 37.18 Non-Industry Players: Distribution by Source of Cell
• Table 37.19 Non-Industry Players: Distribution by Scale of Operation
• Table 37.20 Non-Industry Players: Distribution by Type of Additional Service Offered
• Table 37.21 Cell Therapy Manufacturing (Industry Players): Distribution by Regulatory Authorities / Certifications
• Table 37.22 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Regulatory Authorities / Certifications
• Table 37.23 WuXi AppTec (parent company of Advanced Therapies): Annual Revenues, FY 2022 - H1 FY 2025 (RMB Billion)
• Table 37.24 AGC Biologics: Annual Revenues, FY 2022 - H1 FY 2025 (JPY Billion)
• Table 37.25 Catalent: Annual Revenues, FY 2021 - Q1 FY 2025 (USD Billion)
• Table 37.26 Charles River Laboratories: Annual Revenues, FY 2022- H1 FY 2025 (USD Billion)
• Table 37.27 ImmunityBio: Annual Revenues, FY 2023- H1 FY 2025 (USD Million)
• Table 37.28 Merck KGaA (Parent company of Merck Millipore): Annual Revenues, FY 2022- H1 FY 2025 (EUR Billion)
• Table 37.29 Thermo Fisher Scientific: Annual Revenues, FY 2022 - 9M FY 2025 (JPY Billion)
• Table 37.30 Evotec: Annual Revenues, FY 2022 - H1 FY 2025 (EUR Million)
• Table 37.31 Lonza: Annual Revenues, FY 2022 - H1 FY 2025 (CHF Billion)
• Table 37.32 Sartorius: Annual Revenues, FY 2022 - 9M FY 2025 (EUR Billion)
• Table 37.33 Astellas Pharma: Annual Revenues, FY 2022 - Q1 FY 2025 (YEN Billion)
• Table 37.34 Pharmaron: Annual Revenues, FY 2022 - H1 FY 2025 (RMB Billion)
• Table 37.35 Takara Bio: Annual Revenues, FY 2023 - Q1 FY 2026 (YEN Billion)
• Table 37.36 Clinical Trial Analysis: Distribution by Trial Registration Year, Since 2021
• Table 37.37 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Since 2021
• Table 37.38 Clinical Trial Analysis: Distribution by Trial Status
• Table 37.39 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
• Table 37.40 Clinical Trial Analysis: Distribution by Trial Phase
• Table 37.41 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
• Table 37.42 Clinical Trial Analysis: Distribution by Patient Gender
• Table 37.43 Clinical Trial Analysis: Distribution by Type of Allocation
• Table 37.44 Clinical Trial Analysis: Distribution by Type of Intervention Model
• Table 37.45 Clinical Trial Analysis: Distribution by Type of Masking
• Table 37.46 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
• Table 37.47 Most Active Industry Players: Distribution by Number of Registered Trials
• Table 37.48 Most Active Non-Industry Players: Distribution by Number of Registered Trials
• Table 37.49 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
• Table 37.50 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
• Table 37.51 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
• Table 37.52 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2021
• Table 37.53 Partnerships and Collaborations: Distribution by Type of Partnership
• Table 37.54 Partnerships and Collaborations: Distribution by Year and Type of Partnership
• Table 37.55 Partnerships and Collaborations: Distribution by Type of Immune Cell
• Table 37.56 Partnerships and Collaborations: Distribution by Scale of Operation
• Table 37.57 Most Active Players: Distribution by Number of Partnerships
• Table 37.58 Partnerships and Collaborations: Local and International Agreements
• Table 37.59 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
• Table 37.60 Recent Expansions: Cumulative Year-wise Trend, Since 2021
• Table 37.61 Recent Expansions: Distribution by Type of Expansion
• Table 37.62 Recent Expansions: Distribution by Year and Type of Expansion
• Table 37.63 Recent Expansions: Distribution by Location of Expanded Facility (Region)
• Table 37.64 Recent Expansions: Distribution by Location of Expanded Facility (Country)
• Table 37.65 Recent Expansions: Distribution by Type of Expansion and Location of Headquarters (Country)
• Table 37.66 Recent Expansions: Distribution by Type of Immune Cell
• Table 37.67 Recent Expansions: Distribution by Type of Expansion and Type of Immune Cell
• Table 37.68 Recent Expansions: Distribution by Scale of Operation
• Table 37.69 Most Active Players: Distribution by Number of Expansions
• Table 37.70 Most Active Players: Distribution by Area of Expansion (in sq ft)
• Table 37.71 Big Pharma Initiatives: Distribution by Year of Initiative
• Table 37.72 Big Pharma Initiatives: Distribution by Type of Initiative
• Table 37.73 Big Pharma Initiatives: Distribution by Year and Type of Initiative
• Table 37.74 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Initiatives
• Table 37.75 Big Pharma Initiatives: Distribution by Type of Partnership
• Table 37.76 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Partnerships
• Table 37.77 Big Pharma Initiatives: Distribution by Type of Facility Expansion
• Table 37.78 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Facility Expansion
• Table 37.79 Big Pharma Initiatives: Distribution of Big Pharma Players by Region of Facility Expansion
• Table 37.80 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Mergers and Acquisitions
• Table 37.81 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Funding and Investment
• Table 37.82 Big Pharma Initiatives: Distribution by Type of Immune Cell
• Table 37.83 Big Pharma Initiatives: Distribution by Scale of Operation
• Table 37.84 Big Pharma Initiatives: Distribution of Big Pharma Players by Scale of Operation
• Table 37.85 Big Pharma Initiatives Summary
• Table 37.86 Global Installed Capacity of Industry Players for Cell Therapy Manufacturing: Distribution by Range of Installed Capacity
• Table 37.87 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Company Size
• Table 37.88 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Scale of Operation
• Table 37.89 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Location of Manufacturing Facility
• Table 37.90 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Company Size and Location of Manufacturing Facility
• Table 37.91 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Scale of Operation and Location of Manufacturing Facility
• Table 37.92 Global Installed Capacity of Industry Players for Cell Therapy Manufacturing (Cleanroom Area, sq. ft.): Distribution by Company Size and Range of Installed Capacity
• Table 37.93 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Company Size
• Table 37.94 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Scale of Operation
• Table 37.95 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Location of Manufacturing Facility
• Table 37.96 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Company Size and Location of Manufacturing Facility
• Table 37.97 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Scale of Operation and Location of Manufacturing Facility
• Table 37.98 Global Installed Capacity of Non-Industry Players for Cell Therapy Manufacturing: Distribution by Range of Number of Cleanrooms
• Table 37.99 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Number of Cleanrooms): Distribution by Scale of Operation
• Table 37.100 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Number of Cleanrooms): Distribution by Location of Manufacturing Facility
• Table 37.101 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Range of Installed Capacity
• Table 37.102 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Scale of Operation
• Table 37.103 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Location of Manufacturing Facility
• Table 37.104 Global Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (Number of Patients)
• Table 37.105 Global Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Cells in Billion)
• Table 37.106 Global Clinical Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
• Table 37.107 Clinical Demand for Cell Therapy Manufacturing: Distribution by Type of Cell Therapy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
• Table 37.108 Clinical Demand for Cell Therapy Manufacturing: Distribution by Geography, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
• Table 37.109 Global Commercial Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
• Table 37.110 Commercial Demand for Cell Therapy Manufacturing: Distribution by Type of Cell Therapy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
• Table 37.111 Commercial Demand for Cell Therapy Manufacturing: Distribution by Geography, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
• Table 37.112 Global Cell Therapy Manufacturing Market, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.113 Global Cell Therapy Manufacturing Market, Forecasted Estimates (till 2035), Conservative Scenario (USD Million)
• Table 37.114 Global Cell Therapy Manufacturing Market, Forecasted Estimates (till 2035), Optimistic Scenario (USD Million)
• Table 37.115 Cell Therapy Manufacturing Market: Distribution by Type of Cell Therapy
• Table 37.116 Cell Therapy Manufacturing Market for CAR-T Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.117 Cell Therapy Manufacturing Market for Stem Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.118 Cell Therapy Manufacturing Market for TCR Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.119 Cell Therapy Manufacturing Market for TIL Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.120 Cell Therapy Manufacturing Market for Dendritic Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.121 Cell Therapy Manufacturing Market for Other Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.122 Cell Therapy Manufacturing Market: Distribution by Source of Cells
• Table 37.123 Cell Therapy Manufacturing Market for Autologous Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.124 Cell Therapy Manufacturing Market for Allogeneic Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.125 Cell Therapy Manufacturing Market for Other Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.126 Cell Therapy Manufacturing Market: Distribution by Scale of Operation
• Table 37.127 Cell Therapy Manufacturing Market for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.128 Cell Therapy Manufacturing Market for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.129 Cell Therapy Manufacturing Market: Distribution by Type of Manufacturer
• Table 37.130 Cell Therapy Manufacturing Market for Contract Manufacturing Organizations, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.131 Cell Therapy Manufacturing Market for In-House Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.132 Cell Therapy Manufacturing Market: Distribution by Geography
• Table 37.133 Clinical Cell Therapy Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.134 Clinical Cell Therapy Manufacturing Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.135 Clinical Cell Therapy Manufacturing Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.136 Clinical Cell Therapy Manufacturing Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.137 Clinical Cell Therapy Manufacturing Market in Spain, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.138 Clinical Cell Therapy Manufacturing Market in France, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.139 Clinical Cell Therapy Manufacturing Market in Germany, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.140 Clinical Cell Therapy Manufacturing Market in the UK, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.141 Clinical Cell Therapy Manufacturing Market in Italy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.142 Clinical Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.143 Clinical Cell Therapy Manufacturing Market in China, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.144 Clinical Cell Therapy Manufacturing Market in Singapore, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.145 Clinical Cell Therapy Manufacturing Market in South Korea, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.146 Clinical Cell Therapy Manufacturing Market in Israel, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.147 Clinical Cell Therapy Manufacturing Market in Japan, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.148 Clinical Cell Therapy Manufacturing Market in Taiwan, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.149 Clinical Cell Therapy Manufacturing Market in Brazil, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.150 Clinical Cell Therapy Manufacturing Market in Argentina, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.151 Clinical Cell Therapy Manufacturing Market in South Africa, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.152 Commercial Cell Therapy Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.153 Commercial Cell Therapy Manufacturing Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.154 Commercial Cell Therapy Manufacturing Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.155 Commercial Cell Therapy Manufacturing Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.156 Commercial Cell Therapy Manufacturing Market in Germany, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.157 Commercial Cell Therapy Manufacturing Market in France, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.158 Commercial Cell Therapy Manufacturing Market in the UK, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.159 Commercial Cell Therapy Manufacturing Market in Italy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.160 Commercial Cell Therapy Manufacturing Market in Spain, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.161 Commercial Cell Therapy Manufacturing Market in Rest of Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.162 Commercial Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.163 Commercial Cell Therapy Manufacturing Market in China, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.164 Commercial Cell Therapy Manufacturing Market in Japan, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.165 Commercial Cell Therapy Manufacturing Market in Australia, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.166 Commercial Cell Therapy Manufacturing Market in India, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.167 Commercial Cell Therapy Manufacturing Market in South Korea, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Table 37.168 Commercial Cell Therapy Manufacturing Market in Brazil, Historical Trends (since 2024) and Forecasted Estimates (till 2035) (USD Million)

List of Figures

• Figure 2.1 Research Methodology: Project Methodology
• Figure 2.2 Research Methodology: Data Sources for Secondary Research
• Figure 2.3 Research Methodology: Robust Quality Control
• Figure 3.1 Market Dynamics: Forecast Methodology
• Figure 3.2 Market Dynamics: Market Assessment Framework
• Figure 4.1 Lessons Learnt from Past Recessions
• Figure 5.1 Executive Summary: Market Landscape
• Figure 5.2 Executive Summary: Market Trends (I / II)
• Figure 5.3 Executive Summary: Market Trends (II / II)
• Figure 5.4 Executive Summary: Market Forecast and Opportunity Analysis
• Figure 6.1 Classification of Advanced Therapy Medicinal Products (ATMPs)
• Figure 6.2 Decentralized Manufacturing: Process Model
• Figure 6.3 Cell Therapy Manufacturing: Type of Manufacturer
• Figure 6.4 Cell Therapies: Challenges and Drivers
• Figure 6.5 Cell Therapies: Potency as a Critical Quality Attribute
• Figure 6.6 Cell Therapy Manufacturing: Supply Chain Model
• Figure 7.1 Industry Players: Distribution by Year of Establishment
• Figure 7.2 Industry Players: Distribution by Company Size
• Figure 7.3 Industry Players: Distribution by Location of Headquarters (Region)
• Figure 7.4 Industry Players: Distribution by Location of Headquarters (Country)
• Figure 7.5 Industry Players: Distribution by Company Size and Location of Headquarters (Region)
• Figure 7.6 Industry Players: Distribution by Location of Manufacturing Facility (Region)
• Figure 7.7 Industry Players: Distribution by Location of Manufacturing Facility (Country)
• Figure 7.8 Industry Players: Distribution by Type of Immune Cell Offered
• Figure 7.9 Industry Players: Distribution by Source of Cells
• Figure 7.10 Industry Players: Distribution by Scale of Operation
• Figure 7.11 Industry Players: Distribution by Type of Additional Service Offered
• Figure 8.1 Non-Industry Players: Distribution by Year of Establishment
• Figure 8.2 Non-Industry Players: Distribution by Location of Headquarters (Region)
• Figure 8.3 Non-Industry Players: Distribution by Location of Headquarters (Country)
• Figure 8.4 Non-Industry Players: Distribution by Location of Manufacturing Facility (Region)
• Figure 8.5 Non-Industry Players: Distribution by Location of Manufacturing Facility (Country)
• Figure 8.6 Non-Industry Players: Distribution by Type of Immune Cell Offered
• Figure 8.7 Non-Industry Players: Distribution by Source of Cell
• Figure 8.8 Non-Industry Players: Distribution by Scale of Operation
• Figure 8.9 Non-Industry Players: Distribution by Type of Additional Service Offered
• Figure 9.1 Cell Therapy Manufacturing (Industry Players): Distribution by Regulatory Authorities / Certifications
• Figure 9.2 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Regulatory Authorities / Certifications
• Figure 11.1 Key Considerations for Automating Cell Therapy Manufacturing Process
• Figure 11.2 Requirements to Implement Closed Systems in Cell Therapy Manufacturing Processes
• Figure 11.3 Functions of Automated and Closed Systems at Each Step of the Cell Therapy Manufacturing Process
• Figure 11.4 Advantages and Disadvantages of Single-Use System
• Figure 11.5 Growth Drivers and Roadblocks to the Automated and Closed Systems
• Figure 11.6 Cell Therapy Manufacturing: Roadmap for Developing an Automated Device
• Figure 11.7 Cell Therapy Manufacturing: Comparison Between Manual and Automated Processes
• Figure 11.8 Cell Therapy Manufacturing: Comparative Analysis of Manual and Automated Processes Based on Affiliated Costs
• Figure 12.1 WuXi AppTec (parent company of Advanced Therapies): Annual Revenues, FY 2022 - H1 FY 2025 (RMB Billion)
• Figure 12.2 AGC Biologics: Annual Revenues, FY 2022 - H1 FY 2025 (JPY Billion)
• Figure 12.3 Catalent: Annual Revenues, FY 2021 - Q1 FY 2025 (USD Billion)
• Figure 12.4 Charles River Laboratories: Annual Revenues, FY 2022- H1 FY 2025 (USD Billion)
• Figure 12.5 ImmunityBio: Annual Revenues, FY 2023- H1 FY 2025 (USD Million)
• Figure 12.6 Merck KGaA (Parent company of Merck Millipore): Annual Revenues, FY 2022- H1 FY 2025 (EUR Billion)
• Figure 12.7 Thermo Fisher Scientific: Annual Revenues, FY 2022 - 9M FY 2025 (JPY Billion)
• Figure 12.8 Evotec: Annual Revenues, FY 2022 - H1 FY 2025 (EUR Million)
• Figure 12.9 Lonza: Annual Revenues, FY 2022 - H1 FY 2025 (CHF Billion)
• Figure 12.10 Sartorius: Annual Revenues, FY 2022 - 9M FY 2025 (EUR Billion)
• Figure 12.11 Astellas Pharma: Annual Revenues, FY 2022 - Q1 FY 2025 (YEN Billion)
• Figure 12.12 Pharmaron: Annual Revenues, FY 2022 - H1 FY 2025 (RMB Billion)
• Figure 12.13 Takara Bio: Annual Revenues, FY 2023 - Q1 FY 2026 (YEN Billion)
• Figure 13.1 City of Hope: Type of Additional Service Offered
• Figure 13.2 Clinical Cell and Vaccine Production Facility (CVPF): Type of Additional Service Offered
• Figure 13.3 Fraunhofer Institute for Cell Therapy and Immunology: Type of Additional Service Offered
• Figure 13.4 Newcastle Advanced Therapies: Type of Additional Service Offered
• Figure 13.5 NHS Blood and Transplant: Type of Additional Service Offered
• Figure 13.6 Rayne Cell Therapy Suite (King's College London): Type of Additional Service Offered
• Figure 13.7 Scottish National Blood Transfusion Service (SNBTS) Cellular Therapy Facility: Type of Additional Service Offered
• Figure 15.1 Clinical Trial Analysis: Distribution by Trial Registration Year, Since 2021
• Figure 15.2 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Since 2021
• Figure 15.3 Clinical Trial Analysis: Distribution by Trial Status
• Figure 15.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
• Figure 15.5 Clinical Trial Analysis: Distribution by Trial Phase
• Figure 15.6 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
• Figure 15.7 Clinical Trial Analysis: Distribution by Patient Gender
• Figure 15.8 Clinical Trial Analysis: Distribution by Type of Allocation
• Figure 15.9 Clinical Trial Analysis: Distribution by Type of Intervention Model
• Figure 15.10 Clinical Trial Analysis: Distribution by Type of Masking
• Figure 15.11 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
• Figure 15.12 Most Active Industry Players: Distribution by Number of Registered Trials
• Figure 15.13 Most Active Non-Industry Players: Distribution by Number of Registered Trials
• Figure 15.14 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
• Figure 15.15 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
• Figure 15.16 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
• Figure 16.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2021
• Figure 16.2 Partnerships and Collaborations: Distribution by Type of Partnership
• Figure 16.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
• Figure 16.4 Partnerships and Collaborations: Distribution by Type of Immune Cell
• Figure 16.5 Partnerships and Collaborations: Distribution by Scale of Operation
• Figure 16.6 Most Active Players: Distribution by Number of Partnerships
• Figure 16.7 Partnerships and Collaborations: Local and International Agreements
• Figure 16.8 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
• Figure 17.1 Recent Expansions: Cumulative Year-wise Trend, Since 2021
• Figure 17.2 Recent Expansions: Distribution by Type of Expansion
• Figure 17.3 Recent Expansions: Distribution by Year and Type of Expansion
• Figure 17.4 Recent Expansions: Distribution by Location of Expanded Facility (Region)
• Figure 17.5 Recent Expansions: Distribution by Location of Expanded Facility (Country)
• Figure 17.6 Recent Expansions: Distribution by Type of Expansion and Location of Headquarters (Country)
• Figure 17.7 Recent Expansions: Distribution by Type of Immune Cell
• Figure 17.8 Recent Expansions: Distribution by Type of Expansion and Type of Immune Cell
• Figure 17.9 Recent Expansions: Distribution by Scale of Operation
• Figure 17.10 Most Active Players: Distribution by Number of Expansions
• Figure 17.11 Most Active Players: Distribution by Area of Expansion (in sq ft)
• Figure 18.1 Big Pharma Initiatives: Distribution by Year of Initiative
• Figure 18.2 Big Pharma Initiatives: Distribution by Type of Initiative
• Figure 18.3 Big Pharma Initiatives: Distribution by Year and Type of Initiative
• Figure 18.4 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Initiatives
• Figure 18.5 Big Pharma Initiatives: Distribution by Type of Partnership
• Figure 18.6 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Partnerships
• Figure 18.7 Big Pharma Initiatives: Distribution by Type of Facility Expansion
• Figure 18.8 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Facility Expansion
• Figure 18.9 Big Pharma Initiatives: Distribution of Big Pharma Players by Region of Facility Expansion
• Figure 18.10 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Mergers and Acquisitions
• Figure 18.11 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Funding and Investment
• Figure 18.12 Big Pharma Initiatives: Distribution by Type of Immune Cell
• Figure 18.13 Big Pharma Initiatives: Distribution by Scale of Operation
• Figure 18.14 Big Pharma Initiatives: Distribution of Big Pharma Players by Scale of Operation
• Figure 18.15 Big Pharma Initiatives Summary
• Figure 19.1 Global Installed Capacity of Industry Players for Cell Therapy Manufacturing: Distribution by Range of Installed Capacity
• Figure 19.2 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Company Size
• Figure 19.3 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Scale of Operation
• Figure 19.4 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Location of Manufacturing Facility
• Figure 19.5 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Company Size and Location of Manufacturing Facility
• Figure 19.6 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Scale of Operation and Location of Manufacturing Facility
• Figure 19.7 Global Installed Capacity of Industry Players for Cell Therapy Manufacturing (Cleanroom Area, sq. ft.): Distribution by Company Size and Range of Installed Capacity
• Figure 19.8 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Company Size
• Figure 19.9 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Scale of Operation
• Figure 19.10 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Location of Manufacturing Facility
• Figure 19.11 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Company Size and Location of Manufacturing Facility
• Figure 19.12 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Scale of Operation and Location of Manufacturing Facility
• Figure 19.13 Global Installed Capacity of Non-Industry Players for Cell Therapy Manufacturing: Distribution by Range of Number of Cleanrooms
• Figure 19.14 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Number of Cleanrooms): Distribution by Scale of Operation
• Figure 19.15 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Number of Cleanrooms): Distribution by Location of Manufacturing Facility
• Figure 19.16 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Range of Installed Capacity
• Figure 19.17 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Scale of Operation
• Figure 19.18 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Location of Manufacturing Facility
• Figure 20.1 Global Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (Number of Patients)
• Figure 20.2 Global Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Cells in Billion)
• Figure 20.3 Global Clinical Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
• Figure 20.4 Clinical Demand for Cell Therapy Manufacturing: Distribution by Type of Cell Therapy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
• Figure 20.5 Clinical Demand for Cell Therapy Manufacturing: Distribution by Geography, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
• Figure 20.6 Global Commercial Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
• Figure 20.7 Commercial Demand for Cell Therapy Manufacturing: Distribution by Type of Cell Therapy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
• Figure 20.8 Commercial Demand for Cell Therapy Manufacturing: Distribution by Geography, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
• Figure 21.1 Targeted Therapies: Pricing Model Based on Patient Segment
• Figure 22.1 Make versus Buy Decision Making Framework
• Figure 22.2 Make versus Buy Decision Making: Possible Scenario Descriptions
• Figure 23.1 Total Cost of Ownership: Capital Expenditures (CAPEX)
• Figure 23.2 Total Cost of Ownership: Operational Expenditures (OPEX)
• Figure 23.3 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0-Y20 (USD Million)
• Figure 23.4 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Distribution by CAPEX and OPEX, Y0 and Y20 (USD Million)
• Figure 23.5 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)
• Figure 23.6 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
• Figure 24.1 Cell Therapy Manufacturing: SWOT Analysis
• Figure 24.2 Comparison of SWOT Factors: Harvey Ball Analysis
• Figure 25.1 Survey Insights: Distribution of Respondents by Type of Organization
• Figure 25.2 Survey Insights: Distribution of Respondents by Location of Manufacturing Facility
• Figure 25.3 Survey Insights: Distribution by Designation and Seniority of Respondents
• Figure 25.4 Survey Insights: Distribution by Type of Cell Therapy
• Figure 25.5 Survey Insights: Distribution by Scale of Operation
• Figure 25.6 Survey Insights: Distribution by Source of Cells
• Figure 25.7 Survey Insights: Distribution by Cell Culture System
• Figure 26.1 Global Cell Therapy Manufacturing Market, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 26.2 Global Cell Therapy Manufacturing Market, Forecasted Estimates (till 2035), Conservative Scenario (USD Million)
• Figure 26.3 Global Cell Therapy Manufacturing Market, Forecasted Estimates (till 2035), Optimistic Scenario (USD Million)
• Figure 27.1 Cell Therapy Manufacturing Market: Distribution by Type of Cell Therapy
• Figure 27.2 Cell Therapy Manufacturing Market for CAR-T Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 27.3 Cell Therapy Manufacturing Market for Stem Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 27.4 Cell Therapy Manufacturing Market for TCR Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 27.5 Cell Therapy Manufacturing Market for TIL Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 27.6 Cell Therapy Manufacturing Market for Dendritic Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 27.7 Cell Therapy Manufacturing Market for Other Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 28.1 Cell Therapy Manufacturing Market: Distribution by Source of Cells
• Figure 28.2 Cell Therapy Manufacturing Market for Autologous Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 28.3 Cell Therapy Manufacturing Market for Allogeneic Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 28.4 Cell Therapy Manufacturing Market for Other Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 29.1 Cell Therapy Manufacturing Market: Distribution by Scale of Operation
• Figure 29.2 Cell Therapy Manufacturing Market for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 29.3 Cell Therapy Manufacturing Market for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 30.1 Cell Therapy Manufacturing Market: Distribution by Type of Manufacturer
• Figure 30.2 Cell Therapy Manufacturing Market for Contract Manufacturing Organizations, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 30.3 Cell Therapy Manufacturing Market for In-House Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.1 Cell Therapy Manufacturing Market: Distribution by Geography
• Figure 31.2 Clinical Cell Therapy Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.3 Clinical Cell Therapy Manufacturing Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.4 Clinical Cell Therapy Manufacturing Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.5 Clinical Cell Therapy Manufacturing Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.6 Clinical Cell Therapy Manufacturing Market in Spain, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.7 Clinical Cell Therapy Manufacturing Market in France, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.8 Clinical Cell Therapy Manufacturing Market in Germany, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.9 Clinical Cell Therapy Manufacturing Market in the UK, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.10 Clinical Cell Therapy Manufacturing Market in Italy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.11 Clinical Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.12 Clinical Cell Therapy Manufacturing Market in China, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.13 Clinical Cell Therapy Manufacturing Market in Singapore, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.14 Clinical Cell Therapy Manufacturing Market in South Korea, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.15 Clinical Cell Therapy Manufacturing Market in Israel, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.16 Clinical Cell Therapy Manufacturing Market in Japan, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.17 Clinical Cell Therapy Manufacturing Market in Taiwan, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.18 Clinical Cell Therapy Manufacturing Market in Brazil, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.19 Clinical Cell Therapy Manufacturing Market in Argentina, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.20 Clinical Cell Therapy Manufacturing Market in South Africa, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.21 Commercial Cell Therapy Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.22 Commercial Cell Therapy Manufacturing Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.23 Commercial Cell Therapy Manufacturing Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.24 Commercial Cell Therapy Manufacturing Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.25 Commercial Cell Therapy Manufacturing Market in Germany, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.26 Commercial Cell Therapy Manufacturing Market in France, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.27 Commercial Cell Therapy Manufacturing Market in the UK, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.28 Commercial Cell Therapy Manufacturing Market in Italy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.29 Commercial Cell Therapy Manufacturing Market in Spain, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.30 Commercial Cell Therapy Manufacturing Market in Rest of Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.31 Commercial Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.32 Commercial Cell Therapy Manufacturing Market in China, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.33 Commercial Cell Therapy Manufacturing Market in Japan, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.34 Commercial Cell Therapy Manufacturing Market in Australia, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.35 Commercial Cell Therapy Manufacturing Market in India, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.36 Commercial Cell Therapy Manufacturing Market in South Korea, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
• Figure 31.37 Commercial Cell Therapy Manufacturing Market in Brazil, Historical Trends (since 2024) and Forecasted Estimates (till 2035) (USD Million)
• Figure 35.1 Conclusion: Market Landscape (Industry Players)
• Figure 35.2 Conclusion: Market Landscape (Non-Industry Players)
• Figure 35.3 Conclusion: Clinical Trial Analysis
• Figure 35.4 Conclusion: Partnerships and Collaborations
• Figure 35.5 Conclusion: Recent Expansions
• Figure 35.6 Conclusion: Big Pharma Initiatives
• Figure 35.7 Conclusion: Capacity Analysis
• Figure 35.8 Conclusion: Demand Analysis
• Figure 35.9 Conclusion: Total Cost of Ownership
• Figure 35.10 Conclusion: Market Sizing and Opportunity Analysis